Page last updated: 2024-12-06

cefaclor anhydrous

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cefaclor anhydrous is a semi-synthetic cephalosporin antibiotic that is used to treat a variety of bacterial infections, including otitis media, pharyngitis, and sinusitis. It is effective against a wide range of gram-positive and gram-negative bacteria. Cefaclor is synthesized by chemical modification of the naturally occurring cephalosporin C. It is a broad-spectrum antibiotic, meaning it is effective against a wide range of bacteria. Cefaclor is well-absorbed after oral administration and reaches therapeutic concentrations in most tissues and organs. Cefaclor is generally well-tolerated, but common side effects include diarrhea, nausea, and vomiting. Cefaclor is an important antibiotic because it is effective against a wide range of bacteria and is well-absorbed after oral administration. It is studied to understand its efficacy and safety, and to develop new antibiotics that are more effective and have fewer side effects.'

Cefaclor: Semisynthetic, broad-spectrum antibiotic derivative of CEPHALEXIN. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cefaclor : A cephalosporin bearing chloro and (R)-2-amino-2-phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID51039
CHEMBL ID680
CHEBI ID3478
SCHEMBL ID33540
MeSH IDM0585637

Synonyms (132)

Synonym
BRD-K20338176-002-03-5
BPBIO1_000385
DIVK1C_007043
dystaclor mr
s-6472 ,
l-kefral
BSPBIO_000349
BSPBIO_003276
(6r,7r)-7-{[(2r)-2-amino-2-phenylacetyl]amino}-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
SPECTRUM_001070
SPECTRUM5_001727
BPBIO1_001326
PRESTWICK3_001102
BSPBIO_001204
PRESTWICK2_000485
PRESTWICK2_001102
PRESTWICK3_000485
MLS001424193
53994-73-3
C06877
cefaclor
panoral
kefral
alfacet
(6r,7r)-7-[[(2r)-2-amino-2-phenyl-acetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
cephaclor
s 6472
5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2r)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-, (6r,7r)-
DB00833
3-chloro-7-d-(2-phenylglycinamido)-3-cephem-4-carboxylic acid
NCGC00022612-04
cefaclor anhydrous
D00256
CCL ,
cefaclor (jp17)
alenfral (tn)
cefaclorum [inn-latin]
ceclor cd
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-chloro-8-oxo-, (6r-(6-alpha,7-beta(r*)))-
einecs 258-909-5
(6r,7r)-7-((r)-2-amino-2-phenylacetamido)-3-chloro-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
smr000058250
MLS000069617 ,
KBIOSS_001550
KBIOGR_000386
KBIO2_001550
KBIO2_006686
KBIO3_002777
KBIO1_001987
KBIO2_004118
PRESTWICK1_001102
PRESTWICK0_001102
SPBIO_001237
SPECTRUM3_001858
SPECTRUM2_001189
PRESTWICK0_000485
PRESTWICK1_000485
SPBIO_002270
SPECTRUM4_000093
SPECPLUS_000947
SPBIO_003082
SPECTRUM1500771
NCGC00022612-07
NCGC00022612-06
NCGC00022612-05
AB00052174
HMS2052C11
HMS2092K08
CHEBI:3478 ,
7beta-{[(2r)-2-amino-2-phenylacetyl]amino}-3-chloro-3,4-didehydrocepham-4-carboxylic acid
cefaclorum
HMS1921G22
HMS1571M06
(6r,7r)-7-[[(2r)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6r,7r)-7-[[(2r)-2-azaniumyl-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
7-((2r)-2-amino-2-phenylacetylamino)(7r,7ar)-3-chloro-6-oxo-2h,7h-azetidino[2, 1-b]1,3-thiazine-4-carboxylic acid
C-2461
CHEMBL680
BCP9000501
pharmakon1600-01500771
nsc757422
tox21_110880
dtxsid3022748 ,
dtxcid002748
cas-53994-73-3
HMS2233M13
CCG-40264
unii-3z6fs3ik0k
cefaclor [inn]
3z6fs3ik0k ,
BCPP000294
NCGC00022612-10
cefaclor [jan]
cefaclor [mi]
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2r)-2-amino-2-phenylacetyl)amino)-3-chloro-8-oxo-, (6r,7r)-
cefaclor impurity c [ep impurity]
(6r,7r)-7-(((2r)-2-amino-2-phenylacetyl)amino)-3-chloro-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
cefaclor [who-dd]
EPITOPE ID:117133
HY-B0198
NC00354
SCHEMBL33540
NCGC00022612-11
tox21_110880_1
cefaclor, antibiotic for culture media use only
bdbm42131
cid_51039
QYIYFLOTGYLRGG-GPCCPHFNSA-N
(6r,7r)-7-[(r)-2-amino-2-phenylacetamido]-3-chloro-8-oxo-5-thia-1-azabicyclo[4,2,0]oct-2-ene-2-carboxylic acid
AKOS024282614
(6r,7r)-7-((r)-2-amino-2-phenylacetamido)-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
AB00052174_16
AB00052174_15
(6r,7r)-7-[(2r)-2-amino-2-phenylacetamido]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
cefaclor, analytical reference material
sr-05000001556
SR-05000001556-1
AS-74992
SBI-0051606.P002
Q415167
cefaclor,(s)
143059-69-2
7-(d-2-amino-2-phenylacetamido)-3-chloro-3-cephem-4-carboxylic
NCGC00015260-22
5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,7-[[(2r)-aminophenylacetyl]amino]-3-chloro-8-oxo-, (6r,7r)-
53994-73-3 (free)
A900728
(6r,7r)-7-((s)-2-amino-2-phenylacetamido)-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
EN300-19651305
cefaclorimpurityc
8xi ,
C3478

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The results of these studies indicate that cefaclor has a low toxic potential in the species tested."( An evaluation of the toxicity of cefaclor in laboratory animals.
Gibson, WR; Hanasono, GK; Hoffman, DG; Morton, DM; Owen, NV, 1979
)
0.26
" There were no significant differences between the cefaclor AF- and cefaclor-treated groups in the frequency of adverse events by body system for all events reported."( Comprehensive safety profile of cefaclor AF in respiratory, urinary tract and skin infections.
Dere, WH; Senetar, JE; Stotka, JL; Therasse, DG, 1992
)
0.28
" Treatment-related adverse events were reported for 7% of patients in the lomefloxacin group and 5% in the cefaclor group."( Safety and efficacy of lomefloxacin versus cefaclor in the treatment of acute exacerbations of chronic bronchitis.
Ellison, WT; Gotfried, MH, 1992
)
0.28
" Study drug-related adverse events were experienced by 33."( An open comparative study of the efficacy and safety of sultamicillin versus cefaclor in the treatment of acute otitis media in children.
Biolcati, AH, 1992
)
0.28
" The response to therapy and adverse reaction rate did not differ between groups."( Prospective randomized study comparing the efficacy and safety of ciprofloxacin with cefaclor in the treatment of patients with purulent bronchitis.
Davis, RL; Neidhart, MM; Quenzer, RW,
)
0.13
" Adverse events were minor and comparable among the treatment groups."( A multicenter trial comparing the efficacy and safety of cefuroxime axetil and cefaclor in pneumonia of adults.
Anthony, W; Lowe, J; Nolen, TM; Schleupner, C; Tan, JS; Yangco, BG,
)
0.13
" Adverse effects were not reported during the study."( Safety and efficacy of cefixime versus cefaclor in respiratory tract infections.
Dorow, P, 1989
)
0.28
" The present report describes the effects of transient ureteral obstruction, which increases intracellular concentrations of secreted organic anions, on the cortical uptake and the proximal tubular toxicity of several cephalosporins given in mildly toxic doses."( Effects of ureteral obstruction on the toxicity of cephalosporins in the rabbit kidney.
Hsu, CY; Prime, DJ; Tune, BM; Wang, PL, 1982
)
0.26
" There were no significant differences in the incidence or severity of drug-related adverse events, which, when reported, were mild and transient."( Comparative efficacy and safety of cefprozil versus penicillin, cefaclor and erythromycin in the treatment of streptococcal pharyngitis and tonsillitis.
McCarty, JM, 1994
)
0.29
" Adverse experiences were, in general, few and mild, being reported in 8% and 17% of patients receiving ceftibuten and cefaclor, respectively."( Comparison of the efficacy and safety of ceftibuten and cefaclor in the treatment of pneumonia and bronchiectasis.
McCabe, R; Mogabgab, W; Perrotta, R; Rumans, L, 1993
)
0.29
" No patient in either treatment group withdrew from the study because of adverse events."( A comparative study of the efficacy, safety and tolerability of azithromycin and cefaclor in the treatment of children with acute skin and/or soft tissue infections.
Montero, L, 1996
)
0.29
" Only 15 non-serious adverse events were observed in 160 patients, none of the cases necessitated discontinuation of drug."( The efficacy and safety of cefaclor in respiratory infections amongst Pakistani children.
Aqil, S; Bukhari, KA; Gaba, I; Hassan, M; Hassan, S; Iqbal, A; Khan, MK; Khawar, N; Malik, BA; Malik, S; Masood, T; Najam, Y; Sharif, MW; Tarar, MA; Walla, FL, 2000
)
0.31
"Cefaclor was found to be a safe and efficacious drug in the treatment of bacterial respiratory tract infections amongst Pakistani children."( The efficacy and safety of cefaclor in respiratory infections amongst Pakistani children.
Aqil, S; Bukhari, KA; Gaba, I; Hassan, M; Hassan, S; Iqbal, A; Khan, MK; Khawar, N; Malik, BA; Malik, S; Masood, T; Najam, Y; Sharif, MW; Tarar, MA; Walla, FL, 2000
)
0.31
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" CMC was found toxic for APC at 5 and 7 days, whereas mCMC did not affect the cell viability."( Cytotoxicity of intracanal dressings on apical papilla cells differ upon activation with E. faecalis LTA.
Caldeira, CL; Oliveira, AP; Sipert, CR, 2019
)
0.51

Pharmacokinetics

ExcerptReferenceRelevance
"1 min; the half-life was 42."( [Pharmacokinetics of cefaclor and initial therapeutical experience (author's transl)].
Köppe, P; Lode, H; Stahlmann, R, 1979
)
0.26
" Due to a short elimination half-life and wide therapeutic index, dosage adjustments are not necessary in patients exhibiting moderate renal dysfunction."( Pharmacokinetics of cefaclor AF: effects of age, antacids and H2-receptor antagonists.
Cerimele, BJ; Coleman, DL; DeSante, KA; Hatcher, BL; Kisicki, J; Satterwhite, JH, 1992
)
0.28
"Bacteriological, pharmacokinetic and clinical studies on cefdinir (CFDN, FK482), a new oral cephalosporin, 5% and 10% granules, were performed in the field of pediatrics."( [Bacteriological, pharmacokinetic and clinical studies of 5% and 10% granules of cefdinir in the pediatric field].
Hatakeyama, K; Hori, M; Nakano, K; Sakaguchi, N; Sugita, M; Toyonaga, Y; Yamazaki, M; Yamori, K, 1992
)
0.28
" For the pharmacokinetic analysis of those data, it was necessary to introduce a transfer process from administration site to absorption site to the conventional model."( Pharmacokinetic analysis of the effects of different foods on absorption of cefaclor.
Narita, N; Oguma, T; Sawaki, M; Yamada, H, 1991
)
0.28
" The elimination half-life of cefprozil (1."( Comparison of cefprozil and cefaclor pharmacokinetics and tissue penetration.
Barbhaiya, RH; Gleason, CR; Pittman, KA; Shukla, UA; Shyu, WC; Wilber, RB, 1990
)
0.28
"The dependence of the antibacterial activity of the two oral cephalosporins cefixime and cefaclor on pharmacokinetic properties was investigated in an in vitro model using strains of enterobacteria and a streptococcal strain."( Comparative activity of cefixime and cefaclor in an in vitro model simulating human pharmacokinetics.
Nies, BA, 1989
)
0.28
" LMOX disappeared from plasma in a monoexponential manner with a half-life of 43 min after intravenous administration at a dose of 50 mg/kg."( Ocular pharmacokinetics of latamoxef and cefaclor in rabbits. Penetration into aqueous humor.
Arai, S; Fukuchi, H; Kimura, M; Kitaura, T; Miyake, K; Tsukiai, S, 1988
)
0.27
" Although the pharmacokinetic characteristics of the drugs after intravenous injection were similar to other beta-lactam antibiotics, significant differences between the cephalosporins examined were found in respect of certain kinetic parameters."( Clinical pharmacokinetics of five oral cephalosporins in calves.
Kurtz, B; Paz, R; Soback, S; Ziv, G, 1987
)
0.27
"The effect of cefaclor on the steady state pharmacokinetics of theophylline was investigated in healthy young adults by comparing the pharmacokinetic parameters as found during a nine days course of theophylline alone and as obtained during co-medication with the antibiotic cefaclor."( Clinical pharmacokinetics of theophylline during co-treatment with cefaclor.
Hempenius, J; Holtkamp, A; Jonkman, JH; Schoenmaker, R; van der Boon, WJ, 1986
)
0.27
"The effect of the antibiotic drug cefaclor on steady state pharmacokinetics of theophylline was studied in healthy adults by comparing the pharmacokinetic parameters as found during a 9 days course of theophylline alone and as obtained during comedication with cefaclor."( No effect of cefaclor on theophylline pharmacokinetics.
Hempenius, J; Holtkamp, A; Jonkman, JH; Schoenmaker, R; van der Boon, WJ, 1985
)
0.27
" This review addresses the clinical pharmacokinetic aspects of drug therapy in haemodialysis patients and considers: (a) the effects of ESRD on the general pharmacokinetics of drugs; (b) dialysis clearance and its impact on drug and metabolite elimination; (c) the definition of dialysability and the criteria for evaluation of drug dialysability; (d) pharmacokinetic parameters which are useful in the prediction of drug dialysability; and (e) the application of pharmacokinetic principles to the adjustment of dosage regimens in haemodialysis patients."( Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.
Lee, CS; Marbury, TC,
)
0.13
" These pharmacokinetic data can be used as a basis to compare the four oral cephalosporins; however, comparative susceptibility data must also be considered."( Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers.
Affrime, MB; Hyatt, JM; Nix, DE; Reidenberg, P; Symonds, WT; Teal, MA; Wilton, JH,
)
0.13
" Cefaclor is not metabolized to a significant degree, but it degrades chemically in the body with an approximate half-life of 2 hours."( Pharmacokinetic profile of cefaclor.
Derendorf, H; Schifferer, H; Sourgens, H, 1997
)
0.3
"The serum pharmacokinetic data presented are generally in agreement with those obtained by other authors with both the cefaclor IR (immediate release) and AF (advanced formulation) or MR (modified release) formulations."( New insight into the clinical pharmacokinetics of cefaclor: tissue penetration.
Esposito, S; Mazzei, T; Novelli, A; Periti, P, 2000
)
0.31
" When cefaclor AF 750 mg twice-daily and cefaclor immediate release 500 mg three-times-a-day are compared there is a skew to the right of the pharmacokinetic profile and higher levels are achieved."( Interrelationship between the pharmacokinetics and pharmacodynamics of cefaclor advanced formulation in patients with acute exacerbation of chronic bronchitis.
Boveri, B; Cazzola, M; Centanni, S; Di Marco, F; Di Perna, F; Diamare, F, 2000
)
0.31
" The present study was designed to test the hypothesis that sustained-release formulations could lead to a more suitable pharmacokinetic profile in the ISF at the relevant target site."( Comparative target site pharmacokinetics of immediate- and modified-release formulations of cefaclor in humans.
Brunner, M; de, lP; Derendorf, H; Eichler, HG; Gross, J; Müller, M; Rehak, E; Thyroff-Friesinger, U, 2002
)
0.31
" The time over MIC (T > MIC) of serum antibiotic concentrations were calculated with pharmacokinetic equation and MIC."( [Comparison of pharmacokinetics/pharmacodynamics of cefdinir, cefpodoxime proxetil and cefaclor against common bacteria of community acquired infections].
Gao, L; Li, Y; Liu, J; Liu, Y; Lü, Y; Xiao, YH, 2004
)
0.32
"To determine the pharmacokinetic interaction between cefaclor and bromhexine in healthy Chinese volunteers."( Pharmacokinetic interaction between cefaclor and bromhexine in healthy Chinese volunteers.
Cao, W; Cheng, ZN; Gong, Q; Guo, X; Hu, ZY; Huang, ZZ; Liu, WF; Wang, LQ; Wang, T, 2007
)
0.34
" There were no significant differences in AUC 0-t and Cmax of CEF in logarithm between the single administration group of CEF and the co-administration group of CEF with BHX."( Pharmacokinetic interaction between cefaclor and bromhexine in healthy Chinese volunteers.
Cao, W; Cheng, ZN; Gong, Q; Guo, X; Hu, ZY; Huang, ZZ; Liu, WF; Wang, LQ; Wang, T, 2007
)
0.34
"There is no significant pharmacokinetic parameter change in the drug absorption, metabolism, and excretion, but Vd/F of CEF significant increases in the co-administration of CEF with BHX."( Pharmacokinetic interaction between cefaclor and bromhexine in healthy Chinese volunteers.
Cao, W; Cheng, ZN; Gong, Q; Guo, X; Hu, ZY; Huang, ZZ; Liu, WF; Wang, LQ; Wang, T, 2007
)
0.34
" Because multiple membrane transporters are involved in the intestinal absorption and renal excretion of beta-lactam antibiotics, we evaluated the potential risk of pharmacokinetic interactions between cranberry juice and the beta-lactams amoxicillin (amoxicilline) and cefaclor."( Effects of cranberry juice on pharmacokinetics of beta-lactam antibiotics following oral administration.
Anderson, GD; Andrew, MA; Grady, RW; Li, M; Phillips, B; Salinger, DH; Shen, DD; Vicini, P; Wang, J, 2009
)
0.35
" A sensitive and specific method for quantifying cefaclor in human plasma has been devised and successfully applied to a pharmacokinetic study."( Determination of cefaclor by UPLC-MS-MS for a Chinese pharmacokinetic study.
Huang, C; Miao, L; Wang, W, 2014
)
0.4

Compound-Compound Interactions

ExcerptReferenceRelevance
" The drug-drug interactions (DDIs) between simotinib and other drugs in combination and the underlying mechanism of its gastrointestinal toxicity remain unclear."( Drug interaction studies reveal that simotinib upregulates intestinal absorption by increasing the paracellular permeability of intestinal epithelial cells.
Cheng, Z; Li, P; Liu, Z; Zhu, Q, 2014
)
0.4
" Drug combination assays indicated that these derivatives exhibited synergistic antimicrobial activity when used along with meropenem, effectively restoring the activity of carbapenems against the resistant strains tested in a Galleria mellonella larvae in vivo infection model."( Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
Chan, EWC; Chan, KF; Chan, TH; Chen, S; Cheng, Q; Gao, W; Jin, WB; Leung, YC; Qi, XL; Wong, KY; Xu, C; Zheng, Z, 2018
)
0.48

Bioavailability

ExcerptReferenceRelevance
" No difference was observed in the overall bioavailability of the three antibiotics based on comparable FD/V values."( The pharmacokinetics of the oral cephalosporins cefaclor, cephradine and cephalexin.
Dean, S; Kendall, MJ; Selen, A; Welling, PG; Wise, R, 1979
)
0.26
" Calculated pharmacokinetic constants indicate that the absorption rate of cefaclor was nearly the same as that of cephalexin."( Serum and sputum levels of cefaclor.
Gatzemeier, U; Simon, C, 1979
)
0.26
" The rate of absorption varied, there being marked differences in the time."( [Investigations on the excretion of cefaclor in human bile (author's transl)].
Fabricius, K; Müller, O; Rückert, U, 1979
)
0.26
"The pharmacokinetics and bioavailability of cefaclor advanced formulation (cefaclor AF) were investigated in two studies, one comparing healthy elderly and younger volunteers and the other assessing the effects of an antacid and H2-receptor antagonist on cefaclor AF bioavailability."( Pharmacokinetics of cefaclor AF: effects of age, antacids and H2-receptor antagonists.
Cerimele, BJ; Coleman, DL; DeSante, KA; Hatcher, BL; Kisicki, J; Satterwhite, JH, 1992
)
0.28
" However, the absorption rate of cefaclor is significantly reduced in the presence of food, while that of cefprozil remains unaltered."( Comparison of the effects of food on the pharmacokinetics of cefprozil and cefaclor.
Barbhaiya, RH; Gleason, CR; Pittman, KA; Shukla, UA; Shyu, WC, 1990
)
0.28
" Bioavailability in mice, rats, dogs, and monkeys was determined after oral or parenteral administration."( Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
Cooper, RD; Counter, FT; Draheim, SE; Eudaly, JA; Johnson, RJ; Kukolja, S; Ott, JL; Pfeil-Doyle, J; Quay, JF; Wright, WE, 1988
)
0.27
" The bioavailability of the drugs was about 35 per cent of the administered dose."( Clinical pharmacokinetics of five oral cephalosporins in calves.
Kurtz, B; Paz, R; Soback, S; Ziv, G, 1987
)
0.27
" Tigemonam was well absorbed in laboratory animals and with its excellent gram-negative spectrum of activity should prove of value in oral antibiotic therapy in humans."( In vivo evaluation of tigemonam, a novel oral monobactam.
Bonner, DP; Clark, JM; Dalvi, M; Olsen, SJ; Sykes, RB; Weinberg, DS; Whitney, RR, 1987
)
0.27
" There were no significant differences between capsule and granule forms of S6472 regarding Cmax and AUC, and it was confirmed that bioavailability of both preparations was the same."( [Phase I clinical studies of S6472 (sustained release preparations of cefaclor)].
Iida, M; Ito, M; Matsuda, S; Ohtomo, M; Sonoyama, T; Yasuda, M, 1985
)
0.27
" It is well absorbed when given orally on an empty stomach; absorption is delayed by the presence of food."( Evaluation of cefaclor.
Derry, JE, 1981
)
0.26
" It is concluded that cefaclor is a well absorbed and tolerated cephalosporin for use in newborn infants."( A pharmacological study of cefaclor in the newborn infant.
Chin, KC; Cockburn, F; Kerr, MM; McAllister, TA, 1981
)
0.26
" The significant parameters of bioavailability of an orally administered substance were determined."( [Comparative pharmacokinetics of oral cephalosporins: cephalexin, cefaclor and cefadroxil (author's transl)].
Dzwillo, G; Koeppe, P; Lode, H; Stahlmann, R, 1980
)
0.26
" It is active against virtually all common urinary pathogens, is well absorbed in the upper gastrointestinal tract, is well tolerated and safe."( [Non-comparative open study of the efficacy and tolerance of cefaclor in the prevention of urinary tract infections in children].
Danti, A; Materassi, M; Seracini, D,
)
0.13
"This randomized, open-label, balanced, five-treatment, five-period, five-sequence, single-dose and crossover pharmacokinetic study assessed the effect of different types of food on the bioavailability of cefaclor in 18 healthy male volunteers."( The effect of four different types of food on the bioavailability of cefaclor.
Ahmed, T; Karim, S; Monif, T; Saha, N; Sharma, PL,
)
0.13
"This randomized, six-treatment, six-period, six sequence, single dose, crossover pharmacokinetic study assessed the effect of different types of food on the bioavailability of 500-mg cefaclor extended release tablet in 23 healthy male volunteers."( Comparative effect of different types of food on the bioavailability of cefaclor extended release tablet.
Ahmed, T; Karim, S; Khan, BA; Monif, T; Saha, N; Sharma, PL,
)
0.13
"The utilization of the membrane transport protein PEPT1 as a drug delivery system is a promising strategy to enhance the oral bioavailability of drugs."( Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
Biegel, A; Brandsch, M; Gebauer, S; Hartrodt, B; Neubert, K; Thondorf, I, 2005
)
0.33
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
" On the whole, the inclusion of S-mucin in the composition of the microspheres had an enhancer effect on the release and rectal bioavailability of cefaclor which may be exploited in the design of a rectal delivery system of the drug."( Biodegradable microspheres based on gelatin-porcine mucin admixtures: in vitro and in vivo delivery studies.
Adikwu, MU; Ofokansi, KC; Okorie, O, 2009
)
0.35
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Cefaclor was administered orally in a dosage of 1 to 3 g per day for 7 to 11 days."( Cefaclor: clinical and bacteriological evaluation in 45 cases.
Clavel, A; Espinosa, C; Gómez-Agudo, G; Gómez-Lus, R; Guillen, G; Martinez-Piriz, R, 1979
)
0.26
" The dosage of cefaclor was 20 to 40 mg/kg/day in three or four divided doses for ten days."( Cefaclor in the treatment of susceptible infections in infants and children.
Spencer, MJ, 1979
)
0.26
" The dosage of cefaclor used was either 250 mg or 500 mg taken orally three times daily."( Treatment of acute bronchitis and pneumonia with cefaclor.
Laitinen, L; Mattson, K; Nikander-Hurme, R; Renkonen, OV, 1979
)
0.26
" There was no evidence of any haematological, renal or hepatic toxicity from either drug at the dosage used."( Comparison of cefaclor and amoxycillin in the treatment of urinary infections in a chronic disease hospital.
Lindan, R, 1979
)
0.26
" Total urinary recovery of antibiotic activity accounted for almost 90 percent of dosed cephradine and cephalexin compared to 55 percent of dosed cefaclor."( The pharmacokinetics of the oral cephalosporins cefaclor, cephradine and cephalexin.
Dean, S; Kendall, MJ; Selen, A; Welling, PG; Wise, R, 1979
)
0.26
" At this dosage peak concentrations of 13."( [Serum and tissue concentrations after a single dose of cefaclor].
Bethke, RO; Fabricius, K; Müller, O; Plaue, R, 1979
)
0.26
" The dosage consisted of 500 mg cefaclor three times daily, and the treatment lasted between 4 and 43 days (average 14 days)."( [Experience with cefaclor in the treatment of ear, nose and throat infections. Indications for cefaclor therapy (author's transl)].
Bach, R; Federspil, P; Schätzle, W; Tiesler, E; Weich, C; Wilhelm, HJ, 1979
)
0.26
" Only in one relatively severe case of erysipelas did the disease continue to spread despite the daily doses of 3 x 500 mg of oral cefaclor prescribed by the dosage regimen."( [Cefaclor in dermatological therapy (author's transl)].
Paul, E, 1979
)
0.26
" Cefaclor advanced formulation (cefaclor AF) provides the opportunity for once or twice daily dosing of this agent."( Cefaclor AF: correlation of microbiology and clinical outcome.
Thornsberry, C, 1992
)
0.28
" Due to a short elimination half-life and wide therapeutic index, dosage adjustments are not necessary in patients exhibiting moderate renal dysfunction."( Pharmacokinetics of cefaclor AF: effects of age, antacids and H2-receptor antagonists.
Cerimele, BJ; Coleman, DL; DeSante, KA; Hatcher, BL; Kisicki, J; Satterwhite, JH, 1992
)
0.28
" No significant differences were found between clinical efficacy and safety parameters in the different study groups, and it was concluded that cefaclor AF in a twice-daily or once-daily dosage is as effective and as safe as the currently recommened three-times-a-day dosage of cefaclor."( Comparative trials of cefaclor AF in uncomplicated cystitis and asymptomatic bacteriuria.
Brumfitt, W; Byers, KS; Dere, WH; Hamilton-Miller, JM; Iravani, A, 1992
)
0.28
" Because of its efficacy and once-daily dosing regimen, cefprozil may be an alternative to currently available oral antibiotics in the treatment of UTIs."( Cefprozil versus cefaclor in the treatment of acute and uncomplicated urinary tract infections. Cefprozil Multicenter Study Group.
Doyle, CA; Durham, SJ; Iravani, A; Wilber, RB,
)
0.13
", increased resistance to penicillin and erythromycin and inconvenient dosing schedules) have led to an adjustment in the kinds of antimicrobial agents prescribed for these diseases."( Clinical trials of cefprozil for treatment of skin and skin-structure infections: review.
Nolen, TM, 1992
)
0.28
" With the recommended dosing regimens (cefuroxime axetil at 250 mg and cefaclor at 375 mg twice daily or cefaclor at 250 mg three times daily), cefuroxime concentrations exceed the MIC for 90% of the strains tested for a greater time period than cefaclor concentrations with either regimen."( Pharmacokinetics of cefuroxime axetil and cefaclor: relationship of concentrations in serum to MICs for common respiratory pathogens.
Collins, JJ; Davis, IM; Donn, KH; Hart, RW; James, NC; Lloyd, TL; Powell, JR, 1991
)
0.28
" In this study, mean daily dosage was 40-50 mg/kg for cefaclor and 50 mg/kg ES + 150 mg/kg sulfamide for Pediazole."( [An open randomized trial, Pediazole versus cefaclor in the treatment of acute otitis media in children].
Bedbeder, P; Boucherat, M; Bouhanna, CA; Cohen, R; de La Rocque, F; Geslin, P; Peynegre, R; Reinert, P, 1991
)
0.28
" The dosage of the drug was 40 mg/kg/daily and the duration of the therapy was 10 days."( [Acute maxillary sinusitis treated with cefaclor].
Büyükgebiz, A; Kinik, E, 1990
)
0.28
" If the therapeutic concept is maintained that levels of beta-lactam antibiotics in plasma should exceed the MIC for the offending organisms over a period that approximates the dosing interval, then cefprozil would appear to be suitable for twice-daily administration, whereas cefaclor should probably be administered three or even four times a day."( Phase I study of multiple-dose cefprozil and comparison with cefaclor.
Barbhaiya, RH; Gleason, CR; Martin, RR; Pittman, KA; Shukla, UA; Shyu, WC; Wilber, RB, 1990
)
0.28
" One hundred four children with pharyngitis and serologically confirmed Group A streptococci were randomly treated with cefaclor or penicillin using a mean dosage of 20 mg/kg/day for 10 days."( Comparison of oral cephalosporins with penicillin therapy for group A streptococcal pharyngitis.
Stillerman, M,
)
0.13
"S 6472 granule preparation, a sustained-release cefaclor, was orally administered to 20 acutely exacerbated cases of chronic bronchitis at a daily dosage of 750 mg (titer) in 2 divided doses for a duration of 7-15 days and its clinical usefulness was evaluated."( [Clinical evaluation of S 6472 granule preparation (sustained-release cefaclor) in chronic bronchitis].
Hiraga, Y; Omichi, M; Sasaoka, S, 1988
)
0.27
"The S 6472 granule preparation (sustained-release cefaclor preparation) was administered to 15 cases of chronic bronchitis for its clinical evaluation; a daily dosage of 750 mg was orally given in 2 divided doses after breakfast and dinner for a duration of 7 to 22 days."( [Clinical evaluation of S 6472 granule preparation (sustained-release cefaclor) in chronic bronchitis].
Nakamori, Y; Tanimoto, H, 1988
)
0.27
"S 6472 granule preparation, a sustained-release preparation of cefaclor, was administered to 21 patients with chronic respiratory airway infections for its clinical study; a daily dosage between 750 and 1,500 mg was orally given in 2 divided doses after breakfast and dinner for a duration of 3 to 14 days."( [Clinical study of S 6472 granule preparation (sustained-release cefaclor) in chronic respiratory airway infections].
Ishii, S; Matsunaga, K; Murohashi, K; Numata, H; Odagiri, S; Suzuki, K; Takahashi, K; Yamaki, I, 1988
)
0.27
" The dosage of cefaclor was 40 mg/kg/day administered orally in equally divided doses at 12-hour intervals."( Five vs. ten days of therapy for acute otitis media.
Hendrickse, WA; Kusmiesz, H; Nelson, JD; Shelton, S, 1988
)
0.27
" Provisional oral dosage regimens were computed for each cephalosporin on the basis of the MIC data and the kinetic parameters derived from intravenous and oral drug administration."( Clinical pharmacokinetics of five oral cephalosporins in calves.
Kurtz, B; Paz, R; Soback, S; Ziv, G, 1987
)
0.27
" In the case of cefixime, single daily doses of 400 mg were taken; with cefaclor, the dosage was 250 mg three times daily."( Bowel flora changes in humans receiving cefixime (CL 284,635) or cefaclor.
Edelstein, MA; Finegold, SM; Gee, R; Ingram-Drake, L; MacDonald, K; Reinhardt, J; Wexler, H, 1987
)
0.27
" As the volume of distribution and the clearance were not affected by cefaclor, it is concluded that both drugs can be given concomitantly without any dosage adjustment of theophylline."( Clinical pharmacokinetics of theophylline during co-treatment with cefaclor.
Hempenius, J; Holtkamp, A; Jonkman, JH; Schoenmaker, R; van der Boon, WJ, 1986
)
0.27
" It is concluded that both drugs can be given concomitantly without any dosage adjustment of theophylline."( No effect of cefaclor on theophylline pharmacokinetics.
Hempenius, J; Holtkamp, A; Jonkman, JH; Schoenmaker, R; van der Boon, WJ, 1985
)
0.27
" The important difference between cefadroxil and cefaclor is the remarkably longer half-life of cefadroxil, which makes once-a-day dosing possible and offers greater patient convenience and the likelihood of better compliance."( Comparative efficacy of cefadroxil and cefaclor in the treatment of skin and soft-tissue infections.
Ballantyne, FN, 1985
)
0.27
" Although dosage modification of CCL is necessary in patients with renal dysfunction, multiple doses of 250 mg every 8 hours may be safe and effective even in patients with impaired renal function."( [Cefaclor dosage change with renal dysfunction].
Sekine, O; Usuda, Y, 1985
)
0.27
" Each drug was given in a daily dosage of approximately 40 mg/kg in three divided doses for ten days."( Comparative treatment trial of augmentin versus cefaclor for acute otitis media with effusion.
Kusmiesz, H; Nelson, JD; Odio, CM; Shelton, S, 1985
)
0.27
" On the basis of the above results, it was concluded that S6472 can provide sufficient clinical efficacy when it is administered at daily dosage of 750 mg or 1,500 mg in 2 divided doses after the breakfast and dinner."( [Clinical studies of S6472 in otorhinolaryngologic infections].
Baba, S; Furuta, S; Katsuta, K; Kinoshita, H; Mori, Y; Noboru, T; Ohno, I; Ohyama, M; Suzuki, K; Yamamoto, M, 1985
)
0.27
" Infants were randomly assigned to receive either oral amoxicillin or cefaclor in a dosage of 40 mg/kg/day divided into 3 doses for 10 days."( A controlled trial of cefaclor versus amoxicillin for treatment of acute otitis media in early infancy.
Berman, S; Lauer, BA,
)
0.13
" Cefaclor and amoxicillin were given three times daily before meals in a dosage of 500 and 750 mg respectively for seven days."( Cefaclor versus amoxicillin in the treatment of bacterial pneumonia: a comparative double-blind study.
Leuenberger, P; Vrantchev, S, 1983
)
0.27
" Amoxycillin and cefaclor were given three times daily in a dosage of 375 and 250 mg, respectively, for 7 days."( Influence of amoxycillin and cefaclor on the colonization resistance of oropharynx.
van Saene, HK; Willems, FT; Zweens, J, 1983
)
0.27
" Because of the impaired renal function in ESRD patients, dosage reduction is often recommended to avoid adverse drug reactions, particularly for drugs and active metabolites with extensive renal excretion."( Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.
Lee, CS; Marbury, TC,
)
0.13
" In the CEX group, CEX was orally administered 4 times a day at a daily dosage of 1,000 mg for 3 to 5 days."( [A double-blind comparison between cefaclor and cephalexin in the treatment of dental infections].
Horii, M; Morinaga, T; Nishimura, T; Noshi, Y; Okada, T; Sasaki, T; Shimada, S; Takada, S; Takeuchi, T; Yamanaka, H, 1984
)
0.27
" In 10 patients (from all dosage groups) cefaclor was undetectable in the bronchial mucosa but in every case the serum concentration was low, suggesting incomplete absorption."( Penetration of cefaclor into bronchial mucosa.
Bradbury, R; Funnell, GR; Marlin, GE; Nicholls, AJ, 1984
)
0.27
"The oral cephalosporin derivative Cefaclor was administered to 22 patients with respiratory tract infections at a daily dosage of 3 x 500 mg."( [Report of experiences with the oral cephalosporin-derivative cephaclor in respiratory tract infections].
Spath, P, 1983
)
0.27
" Cefaclor in a twice daily dosage schedule appears to be a safe and useful drug in the treatment of urinary tract infections caused by the common gram-negative organisms and it appears to be as efficacious as the trimethoprim-sulfamethoxazole combination."( A comparison of cefaclor versus trimethoprim-sulfamethoxazole combination in the treatment of acute urinary infections.
Rous, SN, 1981
)
0.26
"The chemistry, pharmacology, pharmacokinetics, bacterial spectrum, clinical use, dosage, adverse reactions, and dosage forms and cost of cefaclor are reviewed."( Evaluation of cefaclor.
Derry, JE, 1981
)
0.26
" In patients on dialysis, dosage interval or quantity should be increased to compensate for doubled drug clearance dialysis."( Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis.
Bolton, WK; Gober, LL; Sande, MA; Scheld, WM; Spyker, DA, 1982
)
0.26
" Dosage and side effect information, in particular, cannot be reliably extrapolated from data derived from studies in adults."( The position of the pharmaceutical industry in the development of drugs for pediatric use.
Christensen, CN, 1980
)
0.26
" In 336 children, 240 received cefetamet pivoxil at 2 dosage levels (10 or 20 mg/kg twice daily) for 7 to 12 days and 96 received the standard comparator, cefaclor (10 mg/kg 3 times daily)."( Comparative clinical efficacy of cefetamet pivoxil in lower respiratory tract infection.
Grassi, GG, 1994
)
0.29
" In two trials, 891 pediatric patients were enrolled to either cefprozil or amoxicillin-clavulanate dosage regimens."( Multi-investigator evaluation of the efficacy and safety of cefprozil, amoxicillin-clavulanate, cefixime and cefaclor in the treatment of acute otitis media.
Kafetzis, DA, 1994
)
0.29
" The abilities of the drugs to protect mice against the organisms were determined in mouse protection tests, and the doses were fractionated to produce various dosing regimens with different times above the MIC."( Optimal times above MICs of ceftibuten and cefaclor in experimental intra-abdominal infections.
Nicolau, DP; Nightingale, CH; Onyeji, CO; Quintiliani, R, 1994
)
0.29
"78 pediatric patients affected by acute otitis media were selected and randomized into two balanced groups of treatment: brodimoprim, at the dosage of 200 mg once-a-day on the first day and of 100 mg once-a-day on the following days, and cefaclor at a dosage of 40 mg/Kg/day in three doses."( Efficacy and tolerability of brodimoprim in bacterial otitis media in children. Controlled study versus cefaclor.
Bergamini, G; Cantini, L; Dallari, S; Galetti, G; Ghidini, A; Martini, A; Mazzoli, M; Monici Preti, PA, 1993
)
0.29
" The less frequent dosing regimen of cefpodoxime may improve patient compliance compared to those antibiotics that require three or four daily doses."( A comparison of cefpodoxime proxetil and cefaclor in the treatment of acute exacerbation of COPD in adults.
Butler, T; Phillips, H; Todd, WM; Van Hook, CJ, 1993
)
0.29
" However, the twice-a-day dosing regimen for cefpodoxime proxetil compared with the three-times-a-day regimen for cefaclor may result in better patient compliance."( Comparison of oral cefpodoxime proxetil and cefaclor in the treatment of skin and soft tissue infections.
Drehobl, M; Pien, F; Stevens, DL, 1993
)
0.29
"In a multicentre, international study of 187 adult patients with bacterial pneumonia or bronchiectasis, the safety and efficacy of a regimen of 200 mg ceftibuten administered twice-daily was compared with cefaclor given in a dosage of 500 mg three times a day."( Comparison of the efficacy and safety of ceftibuten and cefaclor in the treatment of pneumonia and bronchiectasis.
McCabe, R; Mogabgab, W; Perrotta, R; Rumans, L, 1993
)
0.29
" The dosage of 40 mg/kg/day, divided in three equal doses, was employed for both antibiotics in the treatment of acute otitis media, while half of this amount was given once daily for the chemoprophylaxis of recurrent acute otitis media."( Outcome-oriented managed care comparing efficacies of cefaclor and amoxicillin in acute and recurrent acute otitis media.
Moore, GF; Perry, BP; Yonkers, AJ; Zieno, SA, 1995
)
0.29
" Simulated pediatric dosage regimens and target peak concentrations in the central compartment were as follows: penicillin V-potassium, 26 mg/kg of body weight every 6 h (q6h) and 14 micrograms/ml; cefaclor, 13."( Bactericidal activities of cefprozil, penicillin, cefaclor, cefixime, and loracarbef against penicillin-susceptible and -resistant Streptococcus pneumoniae in an in vitro pharmacodynamic infection model.
Cappelletty, DM; Rybak, MJ, 1996
)
0.29
" All patients received cefaclor, as prophylaxis, at the dosage of 10-20 mg/kg/die, administrated as a single bedtime dose."( [Non-comparative open study of the efficacy and tolerance of cefaclor in the prevention of urinary tract infections in children].
Danti, A; Materassi, M; Seracini, D,
)
0.13
" The less frequent dosing schedule of cefpodoxime (bd) compared with cefaclor (tds) appears to be more convenient for the treatment of the infections in children."( Cefpodoxime proxetil suspension compared with cefaclor suspension for treatment of acute otitis media in paediatric patients.
Barreto, DG; de la Torre, C; del Castillo, F; MacLoughlin, GJ; Palma, L; Pinetta, EA, 1996
)
0.29
" All the data have been calculated for the highest recommended oral dosage in France."( Choice of an oral beta-lactam antibiotic for infections due to penicillin-resistant Streptococcus pneumoniae.
Goldstein, FW, 1997
)
0.3
" Clinical trials show similar efficacy of the two formulations in patients with acute exacerbations of chronic bronchitis caused by these organisms, but for this indication a 7-day regimen may be used with the extended-release 500-mg formulation compared with a 10-day dosing regimen with the 250-mg capsule."( Pharmacologic and clinical comparison of cefaclor in immediate-release capsule and extended-release tablet forms.
Cole, P,
)
0.13
" The method is found to be reproducible and convenient for the quantitative analysis of cephalexin and cefaclor in its dosage forms."( HPTLC assay of cephalexin and cefaclor in pharmaceuticals.
Agbaba, D; Eric, S; Vladimirov, S; Zivanov Stakic, D,
)
0.13
" Its pharmacokinetic properties indicate that an 8-hourly dosing schedule is appropriate."( Cefaclor into the millennium.
Brumfitt, W; Hamilton-Miller, JM, 1999
)
0.3
" The less dosing frequency and lower daily price of cefpodoxime provide additional benefits."( Comparison of once daily cefpodoxime proxetil suspension and thrice daily cefaclor suspension in the treatment of acute otitis media in children.
Chiu, HH; Chiu, TF; Hsueh, PR; Huang, LM; Lee, CY; Lee, PI; Lin, HC; Lu, CY; Tsai, HY, 1998
)
0.3
"6 microg/ml, respectively with 200 or 400 mg doses of cefditoren pivoxil; plasma concentrations exceed 1 microg/ml for 4 to 6 hours (33-50% of dosing interval)."( Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species.
Beach, ML; Biedenbach, DJ; Johnson, DM; Jones, RN; Pfaller, MA, 2000
)
0.31
" Cefaclor concentrations in serum persisted above the MIC for more than 40% of dosing interval in 31 subjects, and those in sputum in 24 patients."( Interrelationship between the pharmacokinetics and pharmacodynamics of cefaclor advanced formulation in patients with acute exacerbation of chronic bronchitis.
Boveri, B; Cazzola, M; Centanni, S; Di Marco, F; Di Perna, F; Diamare, F, 2000
)
0.31
"Optimal dosing of beta-lactam antibiotics aims at maximizing the time at which drug levels in the interstitial space fluid (ISF)--the fluid that surrounds the causative microorganisms at the target site--exceed the minimal inhibitory concentration (MIC)."( Comparative target site pharmacokinetics of immediate- and modified-release formulations of cefaclor in humans.
Brunner, M; de, lP; Derendorf, H; Eichler, HG; Gross, J; Müller, M; Rehak, E; Thyroff-Friesinger, U, 2002
)
0.31
" Dosage of azitromycin was 10 mg/kg per day for 3 days and cefaclor 40 mg/kg per day for 10 days."( Etiology of acute otitis media in childhood and evaluation of two different protocols of antibiotic therapy: 10 days cefaclor vs. 3 days azitromycin.
Dündar, G; Erdamar, B; Katircioğlu, S; Oğuz, F; Sidal, M; Süoğlu, Y; Unüvar, E, 2003
)
0.32
" The parameters derived from these experiments were used in a computer-simulation of the antibacterial effects for different dosing regimens and formulations of cefaclor, notably an immediate (IR) and a modified (MR) release formulation."( PK-PD modelling of the effect of cefaclor on four different bacterial strains.
de la Peña, A; Derendorf, H; Gräbe, A; Gross, J; Müller, M; Rand, KH; Rehak, E; Thyroff-Friesinger, U, 2004
)
0.32
" 204 patients were randomly treated with cefaclor given at the dosage of 50 mg/kg/die in two doses for 5 days; 206 patients with 40 mg/kg/die in two doses for 10 days."( [Clinical efficacy and tolerability of short course therapy with cefaclor compared with long-term therapy for treatment of acute otitis media in children].
Catania, S; Gallo, A, 2004
)
0.32
" adipose tissue met the efficacy breakpoint (percentage of the time that free drug concentrations remained above the MIC) for at least 40% of the 8-h dosing interval for organisms with a MIC of 2 mg/liter."( Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
Barbour, A; Derendorf, H; Grant, M; Murthy, B; Sabarinath, SN; Schmidt, S; Seubert, C; Skee, D, 2009
)
0.35
" Therefore, shellac coated chitosan-alginate beads could be considered a successful controlled release oral cefaclor dosage form."( Development of coated beads for oral controlled delivery of cefaclor: In vitro evaluation.
Fahmy, SA; Rasool, BK, 2013
)
0.39
"This study aimed to compare existing dosing regimens of cefaclor with recommended pharmacokinetic/pharmacodynamic (PK/PD) parameters and to see if the proposed dosing regimen could have been the reason for development of bacterial resistance."( Do We Bury Antibacterials When Launching? Cefaclor Example.
Horvat, O; Mikov, M; Sabo, A; Tomas, A; Tomić, N; Tomić, Z; Vukmirović, S, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antibacterial drugA drug used to treat or prevent bacterial infections.
drug allergenAny drug which causes the onset of an allergic reaction.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
cephalosporinA class of beta-lactam antibiotics differing from the penicillins in having a 6-membered, rather than a 5-membered, side ring. Although cephalosporins are among the most commonly used antibiotics in the treatment of routine infections, and their use is increasing over time, they can cause a range of hypersensitivity reactions, from mild, delayed-onset cutaneous reactions to life-threatening anaphylaxis in patients with immunoglobulin E (IgE)-mediated allergy.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (35)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency11.20560.140911.194039.8107AID2451
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency25.11890.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency15.84890.177814.390939.8107AID2147
thioredoxin reductaseRattus norvegicus (Norway rat)Potency50.11870.100020.879379.4328AID588453
phosphopantetheinyl transferaseBacillus subtilisPotency52.06630.141337.9142100.0000AID1490; AID2701; AID2707
RAR-related orphan receptor gammaMus musculus (house mouse)Potency5.44830.006038.004119,952.5996AID1159521
GLS proteinHomo sapiens (human)Potency11.22020.35487.935539.8107AID624170
TDP1 proteinHomo sapiens (human)Potency18.35640.000811.382244.6684AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency31.95030.180013.557439.8107AID1460; AID1468
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency31.83260.011212.4002100.0000AID1030
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency31.62280.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency36.25290.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency33.71360.000723.06741,258.9301AID743085; AID743122
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency31.09890.001815.663839.8107AID894
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency14.12540.354828.065989.1251AID504847
importin subunit beta-1 isoform 1Homo sapiens (human)Potency44.66845.804836.130665.1308AID540263
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency26.67950.168316.404067.0158AID720504
snurportin-1Homo sapiens (human)Potency44.66845.804836.130665.1308AID540263
DNA polymerase eta isoform 1Homo sapiens (human)Potency44.66840.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency10.00000.050127.073689.1251AID588590
DNA polymerase kappa isoform 1Homo sapiens (human)Potency56.23410.031622.3146100.0000AID588579
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency0.00570.005612.367736.1254AID624032
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 isoform 1Homo sapiens (human)IC50 (µMol)7.18402.05808.205241.3880AID540297
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Solute carrier family 15 member 1Homo sapiens (human)IC50 (µMol)8,200.00000.18000.19000.2000AID681608
Solute carrier family 15 member 1Homo sapiens (human)Ki10,000.00000.18003.39339.8000AID238858; AID681115
Solute carrier family 15 member 2Homo sapiens (human)Ki28.92010.79434.22108.0000AID612540
Solute carrier family 15 member 2Rattus norvegicus (Norway rat)Ki29.00003.00006.47788.5000AID681114
Solute carrier family 22 member 8Homo sapiens (human)IC50 (µMol)120.00004.93007.39009.9200AID1209738
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
streptokinase A precursorStreptococcus pyogenes M1 GASEC50 (µMol)75.23250.06008.9128130.5170AID1902; AID1914
Estrogen receptorRattus norvegicus (Norway rat)EC50 (µMol)150.00000.006022.3670130.5170AID1914
Estrogen receptor betaRattus norvegicus (Norway rat)EC50 (µMol)150.00000.006022.3670130.5170AID1914
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (55)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
monoatomic ion transportSolute carrier family 15 member 1Homo sapiens (human)
protein transportSolute carrier family 15 member 1Homo sapiens (human)
peptide transportSolute carrier family 15 member 1Homo sapiens (human)
dipeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
tripeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
proton transmembrane transportSolute carrier family 15 member 1Homo sapiens (human)
monoatomic ion transportSolute carrier family 15 member 2Homo sapiens (human)
protein transportSolute carrier family 15 member 2Homo sapiens (human)
peptide transportSolute carrier family 15 member 2Homo sapiens (human)
peptidoglycan transportSolute carrier family 15 member 2Homo sapiens (human)
xenobiotic transportSolute carrier family 15 member 2Homo sapiens (human)
dipeptide transportSolute carrier family 15 member 2Homo sapiens (human)
renal absorptionSolute carrier family 15 member 2Homo sapiens (human)
regulation of nucleotide-binding domain, leucine rich repeat containing receptor signaling pathwaySolute carrier family 15 member 2Homo sapiens (human)
dipeptide import across plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
tripeptide import across plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
antibacterial innate immune responseSolute carrier family 15 member 2Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 15 member 2Homo sapiens (human)
proton transmembrane transportSolute carrier family 15 member 2Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 8Homo sapiens (human)
response to toxic substanceSolute carrier family 22 member 8Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 8Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 8Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 8Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 8Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 8Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (29)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
proton-dependent oligopeptide secondary active transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
peptide:proton symporter activitySolute carrier family 15 member 1Homo sapiens (human)
tripeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
dipeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
protein bindingSolute carrier family 15 member 2Homo sapiens (human)
peptide:proton symporter activitySolute carrier family 15 member 2Homo sapiens (human)
tripeptide transmembrane transporter activitySolute carrier family 15 member 2Homo sapiens (human)
dipeptide transmembrane transporter activitySolute carrier family 15 member 2Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 8Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
brush borderSolute carrier family 15 member 1Homo sapiens (human)
membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
phagocytic vesicle membraneSolute carrier family 15 member 2Homo sapiens (human)
plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
membraneSolute carrier family 15 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
extracellular exosomeSolute carrier family 15 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 8Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (456)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID529616Antibacterial activity against Beta-lactamase positive Haemophilus influenzae assessed as susceptible isolates after 20 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Low beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains are best detected by testing amoxicillin susceptibility by the broth microdilution method.
AID163754Compound was evaluated for inhibitory activity against PR33 Providencia stuartii1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
3-trifluoromethylcarbacephems: synthesis of broad spectrum antibacterial compounds.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID574560Antibacterial activity against ROB-1 producing ICE- negative Haemophilus influenzae H62 by Etest method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
blaROB-1 presence on pB1000 in Haemophilus influenzae is widespread, and variable cefaclor resistance is associated with altered penicillin-binding proteins.
AID405316Antibacterial activity against Haemophilus influenzae group IIc isolates with ftsI gene mutation by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID132393Efficacy against mouse infected ip with C203 strain of Streptococcus pyogenes, administered po to 19-21-g random sex ICR mice at 1 hr and 5 hr1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID163776In vitro minimal inhibitory concentration (MIC) in brain-heart infusion broth in the presence of hog liver esterase(1:1.5) in Pseudomonas aeruginosa 1041990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporins to carbapenems: 1-oxygenated carbapenems and carbapenams.
AID293554Antibacterial activity against Bacillus subtilis MTCC 121 after 24 hrs by agar dilution assay2007European journal of medicinal chemistry, Jun, Volume: 42, Issue:6
Organoiodine(III) mediated synthesis of 3,9-diaryl- and 3,9-difuryl-bis-1,2,4-triazolo[4,3-a][4,3-c]pyrimidines as antibacterial agents.
AID574558Antibacterial activity against ROB-1 and TEM-1 producing ICE- positive Haemophilus influenzae F52 by Etest method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
blaROB-1 presence on pB1000 in Haemophilus influenzae is widespread, and variable cefaclor resistance is associated with altered penicillin-binding proteins.
AID560489Antibacterial activity against 5 x 10'5 CFU/ml CMY-2 producing Escherichia coli MC4100 harboring plasmid AC-cmy2 by microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase.
AID209641Minimum inhibitory concentration against Streptococcus pyogenes C2031988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID543419Antimicrobial activity against rifampicin-resistant Escherichia coli X1037 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID574573Antibacterial activity against ROB-1 producing ICE- negative Haemophilus influenzae H62 by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
blaROB-1 presence on pB1000 in Haemophilus influenzae is widespread, and variable cefaclor resistance is associated with altered penicillin-binding proteins.
AID561823AUC in plasma of healthy human at 500 mg, po administered at tablet formulation with maximum release by microdialysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
AID571935Antimicrobial activity against Escherichia coli MC4100 harboring promoter hybrid 2 in beta-lactamase GES-1 by Etest2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter.
AID1399270Antimicrobial activity against Klebsiella pneumoniae isolate SJ 3 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID279560Antimicrobial activity against Haemophilus influenzae strains that are normal flora2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID200255In vitro minimal inhibitory concentration (MIC) in brain-heart infusion broth in the presence of hog liver esterase(1:1.5) in Staphylococcus aureus 0051990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporins to carbapenems: 1-oxygenated carbapenems and carbapenams.
AID325151Antimicrobial activity against Haemophilus parasuis BB 10182007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Beta-lactam resistance in Haemophilus parasuis Is mediated by plasmid pB1000 bearing blaROB-1.
AID495323Antimicrobial activity against Beta-lactamase-negative, ampicillin-resistant Haemophilus influenzae by broth microdilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Antimicrobial resistance in Haemophilus influenzae respiratory tract isolates in Korea: results of a nationwide acute respiratory infections surveillance.
AID405313Antibacterial activity against Haemophilus influenzae group I isolates with ftsI gene mutation by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.
AID574579Antibacterial activity against ROB-1 producing ICE- negative Haemophilus influenzae Rd by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
blaROB-1 presence on pB1000 in Haemophilus influenzae is widespread, and variable cefaclor resistance is associated with altered penicillin-binding proteins.
AID535356Antimicrobial activity against Streptococcus pyogenes clinical isolates by broth dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007).
AID574556Antibacterial activity against ROB-1 producing ICE- negative Haemophilus influenzae F50 by Etest method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
blaROB-1 presence on pB1000 in Haemophilus influenzae is widespread, and variable cefaclor resistance is associated with altered penicillin-binding proteins.
AID574555Antibacterial activity against ROB-1 producing ICE- negative Haemophilus influenzae F3 by Etest method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
blaROB-1 presence on pB1000 in Haemophilus influenzae is widespread, and variable cefaclor resistance is associated with altered penicillin-binding proteins.
AID279563Antimicrobial activity against Haemophilus influenzae BLNAR strains2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea.
AID529623Antibacterial activity against Beta-lactamase negative Haemophilus influenzae harboring fst1 mutant gene assessed as resistant isolates after 20 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Low beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains are best detected by testing amoxicillin susceptibility by the broth microdilution method.
AID1653082Antibacterial activity against Bacillus megaterium2019European journal of medicinal chemistry, Feb-15, Volume: 164Isatin derivatives and their anti-bacterial activities.
AID206456In vitro antibacterial activity against the gram-positive bacteria, penicillin resistant Staphylococcus aureus (2619)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID529742Antibacterial activity against Beta-lactamase positive Haemophilus influenzae harboring fst1 mutant gene assessed as resistant isolates after 20 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Low beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains are best detected by testing amoxicillin susceptibility by the broth microdilution method.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID210367In vitro antibacterial activity against the gram-positive bacteria, penicillin sensitive Streptococcus pneumoniae (3273)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID209615In vitro inhibitory activity against Streptococcus pyogenes Park1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Comparative reactivity of 1-carba-1-dethiacephalosporins with cephalosporins.
AID209617In vitro minimal inhibitory concentration (MIC) in brain-heart infusion broth in the presence of hog liver esterase(1:1.5) in Streptococcus pyogenes 2031990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporins to carbapenems: 1-oxygenated carbapenems and carbapenams.
AID525548Antimicrobial activity against ampicillin resistant nontypeable Haemophilus influenzae isolate BB1051 harboring with plasmid pB1000 bearing beta-lactamase ROB-1 by broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Haemophilus influenzae clinical isolates with plasmid pB1000 bearing blaROB-1: fitness cost and interspecies dissemination.
AID207781Compound was evaluated for inhibitory activity against S13E Staphylococcus aureus methicillin resistant penicillin resistant macrolide sensitive (PBP2a producer)1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
3-trifluoromethylcarbacephems: synthesis of broad spectrum antibacterial compounds.
AID529611Antibacterial activity against Beta-lactamase negative Haemophilus influenzae assessed as resistant isolates after 20 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Low beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains are best detected by testing amoxicillin susceptibility by the broth microdilution method.
AID561112Antibacterial activity against Pasteurella multocida BB1046 harboring plasmid pB1003 bearing blaROB-1 gene and plasmid pB1002 bearing strA, sul2 genes by CLSI M31-A3 broth microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Multiresistance in Pasteurella multocida is mediated by coexistence of small plasmids.
AID561107Antibacterial activity against Pasteurella multocida BB1041 harboring plasmid pB1000 bearing blaROB-1 gene and plasmid pB9956 bearing tetH gene by CLSI M31-A3 broth microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Multiresistance in Pasteurella multocida is mediated by coexistence of small plasmids.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID571933Antimicrobial activity against Escherichia coli MC4100 harboring strong promoter in beta-lactamase GES-1 by Etest2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter.
AID290189Antibacterial activity against Staphylococcus aureus MTCC 3160 by agar dilution method2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and characterization of cobalt(II), nickel(II), copper(II) and zinc(II) complexes with Schiff base derived from 4-amino-3-mercapto-6-methyl-5-oxo-1,2,4-triazine.
AID210052Compound was evaluated for inhibitory activity against Park S Streptococcus pneumoniae1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
3-trifluoromethylcarbacephems: synthesis of broad spectrum antibacterial compounds.
AID405302Antibacterial activity against beta-lactamase positive ampicillin resistant Haemophilus influenzae isolate by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.
AID574571Antibacterial activity against ROB-1 producing ICE- positive Haemophilus influenzae F52 by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
blaROB-1 presence on pB1000 in Haemophilus influenzae is widespread, and variable cefaclor resistance is associated with altered penicillin-binding proteins.
AID1399275Antimicrobial activity against Escherichia coli isolate SJ 3 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID394496Antimicrobial activity against Escherichia coli MC4100 harboring pB-acc1 plasmid by agar dilution technique2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID133286Minimum inhibitory concentration against mouse infected with C203 strain of Streptococcus pyogenes1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID1399253Antimicrobial activity against Bacillus anthracis Sterne 34F2 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID612540Binding affinity to human PepT2 in SKTP cells2011Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15
Fragmental modeling of hPepT2 and analysis of its binding features by docking studies and pharmacophore mapping.
AID279561Antimicrobial activity against Haemophilus influenzae BLNAS strains2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea.
AID1209738Inhibition of human OAT3 using estrone-3-sulfate as substrate2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID405318Antibacterial activity against Haemophilus influenzae group III-like isolates with ftsI gene mutation by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.
AID525546Antimicrobial activity against Haemophilus influenzae Rd KW20 harboring with plasmid pB1000 bearing beta-lactamase ROB-1 by broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Haemophilus influenzae clinical isolates with plasmid pB1000 bearing blaROB-1: fitness cost and interspecies dissemination.
AID529612Antibacterial activity against Beta-lactamase negative Haemophilus influenzae isolate after 20 to 24 hrs by Etest method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Low beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains are best detected by testing amoxicillin susceptibility by the broth microdilution method.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID405317Antibacterial activity against Haemophilus influenzae group IId isolates with ftsI gene mutation by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID279559Antimicrobial activity against Haemophilus influenzae strains causing clinical infections2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea.
AID162760In vitro inhibitory activity against Pseudomonas aeruginosa X2581990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Comparative reactivity of 1-carba-1-dethiacephalosporins with cephalosporins.
AID209132Antibacterial activity in mice infected with Streptococcus pyogenes C2031985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Orally absorbable cephalosporin antibiotics. 1. Structure-activity relationships of benzothienyl- and naphthylglycine derivatives of 7-aminodeacetoxycephalosporanic acid.
AID1399267Antimicrobial activity against Stenotrophomonas maltophilia ATCC 700475 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID206460In vitro antibacterial activity against the gram-positive bacteria, penicillin sensitive Staphylococcus aureus (3849)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID543415Antimicrobial activity against rifampicin-resistant Escherichia coli X1037 transconjugant by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID529626Antibacterial activity against Beta-lactamase negative Haemophilus influenzae harboring fst1 mutant gene assessed as resistant isolates after 20 to 24 hrs by Etest method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Low beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains are best detected by testing amoxicillin susceptibility by the broth microdilution method.
AID374589Antimicrobial activity against Staphylococcus epidermidis MTCC 2639 after 24 hrs by agar dilution assay2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
Synthesis and antibacterial activity of some new 2,3-dimethoxy-3-hydroxy-2-(1-phenyl-3-aryl-4-pyrazolyl)chromanones.
AID208931Antibacterial activity in mice infected with Streptococcus pneumoniae Park11985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Orally absorbable cephalosporin antibiotics. 1. Structure-activity relationships of benzothienyl- and naphthylglycine derivatives of 7-aminodeacetoxycephalosporanic acid.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID574567Antibacterial activity against ROB-1 producing ICE- negative Haemophilus influenzae Rd transformant harboring plasmid PB1000 by Etest method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
blaROB-1 presence on pB1000 in Haemophilus influenzae is widespread, and variable cefaclor resistance is associated with altered penicillin-binding proteins.
AID405305Antibacterial activity against beta-lactamase nonproducing ampicillin susceptible Haemophilus influenzae isolate assessed as percent susceptible isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.
AID533205Antimicrobial activity against Haemophilus influenzae clinical isolates assessed as susceptible isolates by PK/PD technique2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007).
AID279562Antimicrobial activity against Haemophilus influenzae BLPAR strains2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea.
AID561830AUC in plasma of healthy human at 750 mg. po administered at tablet formulation with maximum release by microdialysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
AID561828Ratio of fAUC in muscle to fAUC in plasma of healthy human at 500 mg, po administered at tablet formulation with maximum release by microdialysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
AID96084Compound was evaluated for inhibitory activity against X26 Klebsiella pneumoniae1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
3-trifluoromethylcarbacephems: synthesis of broad spectrum antibacterial compounds.
AID1399277Antimicrobial activity against Escherichia coli isolate SJ 5 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID561831fAUC in plasma of healthy human at 750 mg. po administered at tablet formulation with maximum release by microdialysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
AID571934Antimicrobial activity against Escherichia coli MC4100 harboring promoter hybrid 1 in beta-lactamase GES-1 by Etest2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter.
AID535677Antimicrobial activity against beta-lactamase positive Haemophilus influenzae expressing fst1 gene by microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Genotypic versus phenotypic characterization, with respect to beta-lactam susceptibility, of Haemophilus influenzae isolates exhibiting decreased susceptibility to beta-lactam resistance markers.
AID228412Minimum inhibitory concentration against res 76 strain of Haemophilus influenzae1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID93878Minimum inhibitory concentration against X68 strain of Klebsiella pneumoniae1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID68697In vitro inhibitory activity against Escherichia coli EC141990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Comparative reactivity of 1-carba-1-dethiacephalosporins with cephalosporins.
AID405309Antibacterial activity against beta-lactamase nonproducing ampicillin resistant Haemophilus influenzae isolate assessed as percent susceptible isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.
AID208960Antibacterial activity in mice infected with Streptococcus pyogenes C203 after subcutaneous administration1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Orally absorbable cephalosporin antibiotics. 1. Structure-activity relationships of benzothienyl- and naphthylglycine derivatives of 7-aminodeacetoxycephalosporanic acid.
AID495321Antimicrobial activity against beta-lactamase-negative, ampicillin-sensitive Haemophilus influenzae by broth microdilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Antimicrobial resistance in Haemophilus influenzae respiratory tract isolates in Korea: results of a nationwide acute respiratory infections surveillance.
AID67851Minimum inhibitory concentration against EB17 strain of Enterobacter aerogenes1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID535342Antimicrobial activity against Streptococcus pneumoniae clinical isolates assessed as susceptible isolates by broth dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007).
AID132395Efficacy against mouse infected ip with park strain of Streptococcus pneumoniae administered po to 19-21-g random sex ICR mice at 1 hr and 5 hr1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID290190Antibacterial activity against Staphylococcus epidermidis MTCC 2639 by agar dilution method2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and characterization of cobalt(II), nickel(II), copper(II) and zinc(II) complexes with Schiff base derived from 4-amino-3-mercapto-6-methyl-5-oxo-1,2,4-triazine.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID529743Antibacterial activity against Beta-lactamase positive Haemophilus influenzae isolate harboring fst1 mutant gene after 20 to 24 hrs by Etest method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Low beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains are best detected by testing amoxicillin susceptibility by the broth microdilution method.
AID210368In vitro antibacterial activity against the gram-positive bacteria, penicillin sensitive Streptococcus pneumoniae (3512)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID525550Antimicrobial activity against ampicillin resistant serotype-e Haemophilus influenzae isolate BB1053 harboring with plasmid pB1000 bearing beta-lactamase ROB-1 by broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Haemophilus influenzae clinical isolates with plasmid pB1000 bearing blaROB-1: fitness cost and interspecies dissemination.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID163047In vitro inhibitory activity against Proteus rettgeri C241990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Comparative reactivity of 1-carba-1-dethiacephalosporins with cephalosporins.
AID1219874Inhibition of recombinant human ABCC3 expressed in baculovirus infected insect Sf21 cell plasma membrane vesicles assessed as inhibition of transporter-mediated [3H]-estradiol-17beta-glucuronide uptake by liquid scintillation counting analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Oral availability of cefadroxil depends on ABCC3 and ABCC4.
AID561826fAUC in muscle of healthy human at 500 mg, po administered at tablet formulation with maximum release by microdialysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID574557Antibacterial activity against ROB-1 and TEM-1 producing ICE- positive Haemophilus influenzae F48 by Etest method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
blaROB-1 presence on pB1000 in Haemophilus influenzae is widespread, and variable cefaclor resistance is associated with altered penicillin-binding proteins.
AID74715In vitro antibacterial activity was determined by 2 fold serial agar dilution method in gram positive resistant bacteria1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Synthesis and antibacterial activities of new (alpha-hydrazinobenzyl)cephalosporins.
AID529618Antibacterial activity against Beta-lactamase positive Haemophilus influenzae isolate after 20 to 24 hrs by Etest method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Low beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains are best detected by testing amoxicillin susceptibility by the broth microdilution method.
AID96083Compound was evaluated for inhibitory activity against KAE Klebsiella pneumoniae1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
3-trifluoromethylcarbacephems: synthesis of broad spectrum antibacterial compounds.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID279564Antimicrobial activity against Haemophilus influenzae BLPACR strains2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea.
AID529624Antibacterial activity against Beta-lactamase negative Haemophilus influenzae isolate harboring fst1 mutant gene after 20 to 24 hrs by Etest method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Low beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains are best detected by testing amoxicillin susceptibility by the broth microdilution method.
AID525549Antimicrobial activity against ampicillin resistant nontypeable Haemophilus influenzae isolate BB1052 harboring with plasmid pB1000 bearing beta-lactamase ROB-1 by broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Haemophilus influenzae clinical isolates with plasmid pB1000 bearing blaROB-1: fitness cost and interspecies dissemination.
AID405303Antibacterial activity against beta-lactamase nonproducing ampicillin resistant Haemophilus influenzae isolate by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.
AID405301Antibacterial activity against beta-lactamase nonproducing ampicillin susceptible Haemophilus influenzae isolate by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.
AID394493Antimicrobial activity against Escherichia coli MC4100 harboring pA-acc1 plasmid by agar dilution technique2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID1219873Inhibition of recombinant human ABCC2 expressed in insect Sf21 cell plasma membrane vesicles assessed as inhibition of transporter-mediated [3H]-estradiol-17beta-glucuronide uptake by liquid scintillation counting analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Oral availability of cefadroxil depends on ABCC3 and ABCC4.
AID529613Antibacterial activity against Beta-lactamase negative Haemophilus influenzae assessed as susceptible isolates after 20 to 24 hrs by Etest method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Low beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains are best detected by testing amoxicillin susceptibility by the broth microdilution method.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID207784Compound was evaluated for inhibitory activity against X400S Staphylococcus aureus methicillin resistant and macrolide resistant1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
3-trifluoromethylcarbacephems: synthesis of broad spectrum antibacterial compounds.
AID535360Antimicrobial activity against Haemophilus influenzae clinical isolates by broth dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007).
AID200340Minimum inhibitory concentration against X514 strain of Salmonella1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID529615Antibacterial activity against Beta-lactamase positive Haemophilus influenzae isolate after 20 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Low beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains are best detected by testing amoxicillin susceptibility by the broth microdilution method.
AID290193Antibacterial activity against Escherichia coli MTCC 51 by agar dilution method2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and characterization of cobalt(II), nickel(II), copper(II) and zinc(II) complexes with Schiff base derived from 4-amino-3-mercapto-6-methyl-5-oxo-1,2,4-triazine.
AID1679877Covalent inhibition of bacterial NDM-12018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1399280Antimicrobial activity against Escherichia coli ATCC 25922 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID495322Antimicrobial activity against Beta-lactamase-positive, ampicillin-resistant Haemophilus influenzae by broth microdilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Antimicrobial resistance in Haemophilus influenzae respiratory tract isolates in Korea: results of a nationwide acute respiratory infections surveillance.
AID1399265Antimicrobial activity against Pseudomonas aeruginosa PAO1 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID495324Antimicrobial activity against Beta-lactamase-positive, ampicillin-cluvulanate-resistant Haemophilus influenzae by broth microdilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Antimicrobial resistance in Haemophilus influenzae respiratory tract isolates in Korea: results of a nationwide acute respiratory infections surveillance.
AID529745Antibacterial activity against Beta-lactamase positive Haemophilus influenzae harboring fst1 mutant gene assessed as resistant isolates after 20 to 24 hrs by Etest method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Low beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains are best detected by testing amoxicillin susceptibility by the broth microdilution method.
AID574565Antibacterial activity against ROB-1 and TEM-1 producing ICE- positive Haemophilus influenzae F47 by Etest method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
blaROB-1 presence on pB1000 in Haemophilus influenzae is widespread, and variable cefaclor resistance is associated with altered penicillin-binding proteins.
AID405304Antibacterial activity against beta-lactamase producing amoxicillin-clavulanic acid-resistant Haemophilus influenzae isolate by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.
AID200343Minimum inhibitory concentration against Salmonella (X514)1989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
3-Sulfonyl-1-carba-1-dethiacephems.
AID561111Antibacterial activity against Pasteurella multocida BB1045 harboring plasmid pB1000 bearing blaROB-1 gene and plasmid pB9956 bearing tetH gene by CLSI M31-A3 broth microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Multiresistance in Pasteurella multocida is mediated by coexistence of small plasmids.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID85965Compound was evaluated for inhibitory activity against C.L Haemophilus influenzae ampicillin sensitive1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
3-trifluoromethylcarbacephems: synthesis of broad spectrum antibacterial compounds.
AID405314Antibacterial activity against Haemophilus influenzae group IIa isolates with ftsI gene mutation by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.
AID206457In vitro antibacterial activity against the gram-positive bacteria, penicillin resistant Staphylococcus aureus (2672)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID1399259Antimicrobial activity against Streptococcus pyogenes ATCC 700294 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID16865Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Comparative reactivity of 1-carba-1-dethiacephalosporins with cephalosporins.
AID511287Antibacterial activity against Pseudomonas aeruginosa NL68 expressing GES-13 beta lactamase2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID529609Antibacterial activity against Beta-lactamase negative Haemophilus influenzae isolate after 20 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Low beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains are best detected by testing amoxicillin susceptibility by the broth microdilution method.
AID529622Antibacterial activity against Beta-lactamase negative Haemophilus influenzae harboring fst1 mutant gene assessed as susceptible isolates after 20 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Low beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains are best detected by testing amoxicillin susceptibility by the broth microdilution method.
AID529627Antibacterial activity against Beta-lactamase positive Haemophilus influenzae isolate harboring fst1 mutant gene after 20 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Low beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains are best detected by testing amoxicillin susceptibility by the broth microdilution method.
AID588965Substrates of transporters of clinical importance in the absorption and disposition of drugs, OAT32010Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3
Membrane transporters in drug development.
AID394494Antimicrobial activity against Escherichia coli MC4100 harboring pACYC184 plasmid by agar dilution technique2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID207783Compound was evaluated for inhibitory activity against X1.1 Staphylococcus aureus penicillin sensitive1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
3-trifluoromethylcarbacephems: synthesis of broad spectrum antibacterial compounds.
AID574568Antibacterial activity against ROB-1 producing ICE- negative Haemophilus influenzae F3 by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
blaROB-1 presence on pB1000 in Haemophilus influenzae is widespread, and variable cefaclor resistance is associated with altered penicillin-binding proteins.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID525545Antimicrobial activity against Haemophilus influenzae Rd KW20 by broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Haemophilus influenzae clinical isolates with plasmid pB1000 bearing blaROB-1: fitness cost and interspecies dissemination.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID205885Minimum inhibitory concentration against 222 strain of Staphylococcus epidermidis1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID206459In vitro antibacterial activity against the gram-positive bacteria, penicillin sensitive Staphylococcus aureus (3072)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID206461In vitro antibacterial activity against the gram-positive bacteria, penicillin sensitive Staphylococcus aureus (663E)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID529620Antibacterial activity against Beta-lactamase positive Haemophilus influenzae assessed as resistant isolates after 20 to 24 hrs by Etest method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Low beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains are best detected by testing amoxicillin susceptibility by the broth microdilution method.
AID405315Antibacterial activity against Haemophilus influenzae group IIb isolates with ftsI gene mutation by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID325153Antimicrobial activity against Haemophilus parasuis BB 10202007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Beta-lactam resistance in Haemophilus parasuis Is mediated by plasmid pB1000 bearing blaROB-1.
AID1653062Antibacterial activity against Staphylococcus epidermidis2019European journal of medicinal chemistry, Feb-15, Volume: 164Isatin derivatives and their anti-bacterial activities.
AID325155Antimicrobial activity against Haemophilus parasuis BB 10222007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Beta-lactam resistance in Haemophilus parasuis Is mediated by plasmid pB1000 bearing blaROB-1.
AID561099Antibacterial activity against Pasteurella multocida ATCC 43137 by CLSI M31-A3 broth microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Multiresistance in Pasteurella multocida is mediated by coexistence of small plasmids.
AID525547Antimicrobial activity against ampicillin resistant nontypeable Haemophilus influenzae isolate BB1050 harboring with plasmid pB1000 bearing beta-lactamase ROB-1 by broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Haemophilus influenzae clinical isolates with plasmid pB1000 bearing blaROB-1: fitness cost and interspecies dissemination.
AID571937Antimicrobial activity against Escherichia coli MC4100 harboring strong promoter and active promoter P2 in beta-lactamase GES-1 by Etest2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter.
AID1653047Antibacterial activity against Staphylococcus aureus2019European journal of medicinal chemistry, Feb-15, Volume: 164Isatin derivatives and their anti-bacterial activities.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID535673Antimicrobial activity against beta-lactamase negative, ampicillin-resistant Haemophilus influenzae expressing fst1 mutant gene by microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Genotypic versus phenotypic characterization, with respect to beta-lactam susceptibility, of Haemophilus influenzae isolates exhibiting decreased susceptibility to beta-lactam resistance markers.
AID535681Antimicrobial activity against beta-lactamase negative Haemophilus influenzae expressing fst1 gene by microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Genotypic versus phenotypic characterization, with respect to beta-lactam susceptibility, of Haemophilus influenzae isolates exhibiting decreased susceptibility to beta-lactam resistance markers.
AID208312Minimum inhibitory concentration against Streptococcus pneumoniae (PARK)1989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
3-Sulfonyl-1-carba-1-dethiacephems.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID206416Antibacterial activity in mice infected with Staphylococcus aureus 3055 by oral administration1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Orally absorbable cephalosporin antibiotics. 1. Structure-activity relationships of benzothienyl- and naphthylglycine derivatives of 7-aminodeacetoxycephalosporanic acid.
AID561104Antibacterial activity against Pasteurella multocida BB1038 harboring plasmid pB1000 bearing blaROB-1 gene and plasmid pB1005 bearing strA, sul2 genes by CLSI M31-A3 broth microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Multiresistance in Pasteurella multocida is mediated by coexistence of small plasmids.
AID574563Antibacterial activity against ROB-1 and TEM-1 producing ICE- positive Haemophilus influenzae F54 harboring V489G, M503R, R517H, V547I and N569S mutations in PBP3 by Etest method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
blaROB-1 presence on pB1000 in Haemophilus influenzae is widespread, and variable cefaclor resistance is associated with altered penicillin-binding proteins.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID561101Antibacterial activity against Pasteurella multocida BB1035 harboring plasmid pB1000 bearing blaROB-1 gene and plasmid pB1005 bearing strA, sul2 genes by CLSI M31-A3 broth microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Multiresistance in Pasteurella multocida is mediated by coexistence of small plasmids.
AID405307Antibacterial activity against beta-lactamase positive ampicillin resistant Haemophilus influenzae isolate assessed as percent susceptible isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.
AID574566Antibacterial activity against ROB-1 producing ICE- negative Haemophilus influenzae Rd by Etest method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
blaROB-1 presence on pB1000 in Haemophilus influenzae is widespread, and variable cefaclor resistance is associated with altered penicillin-binding proteins.
AID209467In vitro antibacterial activity against the gram-positive bacteria, erythromycin resistant Streptococcus pyogenes1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID68524Minimum inhibitory concentration against Enterobacter cloacae (EB5)1989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
3-Sulfonyl-1-carba-1-dethiacephems.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID529621Antibacterial activity against Beta-lactamase negative Haemophilus influenzae isolate harboring fst1 mutant gene after 20 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Low beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains are best detected by testing amoxicillin susceptibility by the broth microdilution method.
AID66738In vitro minimal inhibitory concentration (MIC) in brain-heart infusion broth in the presence of hog liver esterase(1:1.5) in Enterococcus cloacae 0091990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporins to carbapenems: 1-oxygenated carbapenems and carbapenams.
AID560488Antibacterial activity against 5 x 10'5 CFU/ml CMY-30 producing Escherichia coli MC4100 harboring plasmid AC-cmy30 by microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase.
AID228987Minimum inhibitory concentration against sens CL strain of Haemophilus influenzae1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID1134376Hydrolytic stability of the compound assessed as beta-lactum ring opening rate at pH 10 at 35 degC by UV method1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Hydrolysis of 3-chloro-3-cephems. Intramolecular nucleophilic attack in cefaclor.
AID571938Antimicrobial activity against Escherichia coli MC4100 harboring promoter hybrid 1 and active promoter P2 in beta-lactamase GES-1 by Etest2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter.
AID561832fAUC in muscle of healthy human at 750 mg. po administered at tablet formulation with maximum release by microdialysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
AID529625Antibacterial activity against Beta-lactamase negative Haemophilus influenzae harboring fst1 mutant gene assessed as susceptible isolates after 20 to 24 hrs by Etest method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Low beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains are best detected by testing amoxicillin susceptibility by the broth microdilution method.
AID574578Antibacterial activity against ROB-1 producing ICE- positive Haemophilus influenzae F47 by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
blaROB-1 presence on pB1000 in Haemophilus influenzae is widespread, and variable cefaclor resistance is associated with altered penicillin-binding proteins.
AID574576Antibacterial activity against ROB-1 producing ICE- positive Haemophilus influenzae F54 harboring V489G, M503R, R517H, V547I and N569S mutations in PBP3 by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
blaROB-1 presence on pB1000 in Haemophilus influenzae is widespread, and variable cefaclor resistance is associated with altered penicillin-binding proteins.
AID529617Antibacterial activity against Beta-lactamase positive Haemophilus influenzae assessed as resistant isolates after 20 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Low beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains are best detected by testing amoxicillin susceptibility by the broth microdilution method.
AID325154Antimicrobial activity against Haemophilus parasuis BB 10212007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Beta-lactam resistance in Haemophilus parasuis Is mediated by plasmid pB1000 bearing blaROB-1.
AID1399263Antimicrobial activity against tolC deficient Escherichia coli JW5503-1 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID511290Antibacterial activity against Escherichia coli DH5alpha2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID1209734Inhibition of mouse OAT1 expressed in CHO cells assessed as inhibition of fluorescein uptake at 500 uM over 20 mins relative to untreated-control2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID1399278Antimicrobial activity against Escherichia coli isolate SJ 6 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID208929Antibacterial activity in mice infected with Streptococcus pneumoniae Park1 by subcutaneous administration1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Orally absorbable cephalosporin antibiotics. 1. Structure-activity relationships of benzothienyl- and naphthylglycine derivatives of 7-aminodeacetoxycephalosporanic acid.
AID325152Antimicrobial activity against Haemophilus parasuis BB 10192007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Beta-lactam resistance in Haemophilus parasuis Is mediated by plasmid pB1000 bearing blaROB-1.
AID238858Binding affinity against membrane transport protein PEPT1 in human Caco-2 cells2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
AID30268Compound was evaluated for inhibitory activity against AC12 Acinetobacter1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
3-trifluoromethylcarbacephems: synthesis of broad spectrum antibacterial compounds.
AID394495Antimicrobial activity against Escherichia coli MC4100 harboring pB-acc4 plasmid by agar dilution technique2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID209765Minimum inhibitory concentration against Streptococcus pyogenes (C203)1989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
3-Sulfonyl-1-carba-1-dethiacephems.
AID679005TP_TRANSPORTER: uptake in PEPT1-expressing CHO cells1999Journal of pharmaceutical sciences, Mar, Volume: 88, Issue:3
CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID205895Minimum inhibitory concentration against Staphylococcus epidermidis (222)1989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
3-Sulfonyl-1-carba-1-dethiacephems.
AID1209733Binding affinity to mouse OAT3 expressed in CHO cells at 10 to 1000 uM measured over 20 mins2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID13843Oral bioavailability in mouse1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID1399268Antimicrobial activity against Klebsiella pneumoniae isolate SJ 1 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID486734Antimicrobial activity against Bacillus megaterium after 24 hrs2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Synthesis and antimicrobial activity of cholic acid hydrazone analogues.
AID293550Antibacterial activity against Staphylococcus aureus MTCC 3160 after 24 hrs by agar dilution assay2007European journal of medicinal chemistry, Jun, Volume: 42, Issue:6
Organoiodine(III) mediated synthesis of 3,9-diaryl- and 3,9-difuryl-bis-1,2,4-triazolo[4,3-a][4,3-c]pyrimidines as antibacterial agents.
AID372666Antimicrobial activity against Salmonella typhi MTCC 733 after 24 hrs by agar dilution assay2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
Synthesis and antibacterial activity of some new 2,3-dimethoxy-3-hydroxy-2-(1-phenyl-3-aryl-4-pyrazolyl)chromanones.
AID486730Antimicrobial activity against Pseudomonas aeruginosa after 24 hrs2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Synthesis and antimicrobial activity of cholic acid hydrazone analogues.
AID529610Antibacterial activity against Beta-lactamase negative Haemophilus influenzae assessed as susceptible isolates after 20 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Low beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains are best detected by testing amoxicillin susceptibility by the broth microdilution method.
AID163109Minimum inhibitory concentration against Pseudomonas aeruginosa (X528)1989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
3-Sulfonyl-1-carba-1-dethiacephems.
AID133288Minimum inhibitory concentration against mouse infected with park strain of Streptococcus pneumoniae1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID74702In vitro antibacterial activity was determined by 2 fold serial agar dilution method in gram negative resistant bacteria1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Synthesis and antibacterial activities of new (alpha-hydrazinobenzyl)cephalosporins.
AID144367Minimum inhibitory concentration against N9 strain of Shigella sonnei1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID163053Minimum inhibitory concentration against Proteus rettgeri (C24)1989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
3-Sulfonyl-1-carba-1-dethiacephems.
AID495551Antimicrobial activity against Haemophilus influenzae isolate by broth microdilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Antimicrobial resistance in Haemophilus influenzae respiratory tract isolates in Korea: results of a nationwide acute respiratory infections surveillance.
AID535669Antimicrobial activity against beta-lactamase positive, ampicillin-clavulanic acid resistant Haemophilus influenzae expressing fst1 mutant gene by microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Genotypic versus phenotypic characterization, with respect to beta-lactam susceptibility, of Haemophilus influenzae isolates exhibiting decreased susceptibility to beta-lactam resistance markers.
AID69484Minimum inhibitory concentration against Escherichia coli (EC14)1989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
3-Sulfonyl-1-carba-1-dethiacephems.
AID1653059Antibacterial activity against Pseudomonas aeruginosa2019European journal of medicinal chemistry, Feb-15, Volume: 164Isatin derivatives and their anti-bacterial activities.
AID374590Antimicrobial activity against Bacillus pumilus MTCC 1456 after 24 hrs by agar dilution assay2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
Synthesis and antibacterial activity of some new 2,3-dimethoxy-3-hydroxy-2-(1-phenyl-3-aryl-4-pyrazolyl)chromanones.
AID207832Minimum inhibitory concentration against V41 strain of Staphylococcus aureus1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID369634Antimicrobial activity against Haemophilus influenzae expressing mutant ftsI gene2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Can the Etest correctly determine the MICs of beta-lactam and cephalosporin antibiotics for beta-lactamase-negative ampicillin-resistant Haemophilus influenzae?
AID67087Compound was evaluated for inhibitory activity against 2041 Enterococcus faecalis Gp.D streptococcus penicillin susceptible1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
3-trifluoromethylcarbacephems: synthesis of broad spectrum antibacterial compounds.
AID325161Antimicrobial activity against Haemophilus parasuis BB 10262007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Beta-lactam resistance in Haemophilus parasuis Is mediated by plasmid pB1000 bearing blaROB-1.
AID52807Compound was evaluated for inhibitory activity against CF17 Citrobacter1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
3-trifluoromethylcarbacephems: synthesis of broad spectrum antibacterial compounds.
AID85799In vitro inhibitory activity against Haemophilus influenza C.L1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Comparative reactivity of 1-carba-1-dethiacephalosporins with cephalosporins.
AID1399269Antimicrobial activity against Klebsiella pneumoniae isolate SJ 2 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID69485Minimum inhibitory concentration against Escherichia coli (TEM beta-lactamase containing)1989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
3-Sulfonyl-1-carba-1-dethiacephems.
AID394497Antimicrobial activity against Escherichia coli MC4100 harboring pBCSK plasmid by agar dilution technique2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID74703In vitro antibacterial activity was determined by 2 fold serial agar dilution method with multilocular device in gram negative bacteria1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Synthesis and antibacterial activities of new (alpha-hydrazinobenzyl)cephalosporins.
AID205203Compound was evaluated for inhibitory activity against SE3 Serratia1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
3-trifluoromethylcarbacephems: synthesis of broad spectrum antibacterial compounds.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID535364Antimicrobial activity against Haemophilus influenzae clinical isolates assessed as resistant isolates by broth dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007).
AID575417Antimicrobial activity against anrB-deficient Listeria monocytogenes EGD-e at 30 ug after 16 hrs by disk diffusion assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
The ABC transporter AnrAB contributes to the innate resistance of Listeria monocytogenes to nisin, bacitracin, and various beta-lactam antibiotics.
AID163734Compound was evaluated for inhibitory activity against C24 Providencia rettgeri1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
3-trifluoromethylcarbacephems: synthesis of broad spectrum antibacterial compounds.
AID1399274Antimicrobial activity against Escherichia coli isolate SJ 2 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID535494Antimicrobial activity against beta-lactamase positive, ampicillin-clavulanic acid resistant Haemophilus influenzae expressing fst1 mutant gene assessed as resistant isolates by microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Genotypic versus phenotypic characterization, with respect to beta-lactam susceptibility, of Haemophilus influenzae isolates exhibiting decreased susceptibility to beta-lactam resistance markers.
AID210364In vitro antibacterial activity against the gram-positive bacteria, penicillin resistant Streptococcus pneumoniae (4635)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID543427Antimicrobial activity against Escherichia coli XL-1 Blue harboring plasmid CL1920 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID405312Antibacterial activity against beta-lactamase producing amoxicillin-clavulanic acid-resistant Haemophilus influenzae isolate assessed as percent resistant isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.
AID1209736Inhibition of human OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake at 500 uM over 20 mins relative to untreated-control2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID79397In vitro minimal inhibitory concentration (MIC) in brain-heart infusion broth in the presence of hog liver esterase(1:1.5) in Haemophilus influenzae 1021990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporins to carbapenems: 1-oxygenated carbapenems and carbapenams.
AID325158Antimicrobial activity against Haemophilus parasuis BB 10252007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Beta-lactam resistance in Haemophilus parasuis Is mediated by plasmid pB1000 bearing blaROB-1.
AID535675Antimicrobial activity against beta-lactamase positive Haemophilus influenzae expressing fst1 gene assessed as resistant isolates by microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Genotypic versus phenotypic characterization, with respect to beta-lactam susceptibility, of Haemophilus influenzae isolates exhibiting decreased susceptibility to beta-lactam resistance markers.
AID207057In vitro inhibitory activity against Staphylococcus aureus X1.11990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Comparative reactivity of 1-carba-1-dethiacephalosporins with cephalosporins.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID374588Antimicrobial activity against Staphylococcus aureus MTCC 3160 after 24 hrs by agar dilution assay2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
Synthesis and antibacterial activity of some new 2,3-dimethoxy-3-hydroxy-2-(1-phenyl-3-aryl-4-pyrazolyl)chromanones.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID535671Antimicrobial activity against beta-lactamase negative, ampicillin-resistant Haemophilus influenzae expressing fst1 mutant gene assessed as resistant isolates by microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Genotypic versus phenotypic characterization, with respect to beta-lactam susceptibility, of Haemophilus influenzae isolates exhibiting decreased susceptibility to beta-lactam resistance markers.
AID1399260Antimicrobial activity against Acinetobacter baumannii ATCC 19606 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID511288Antibacterial activity against Escherichia coli DH5alpha pB-ges-13 plasmid2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID535340Antimicrobial activity against Streptococcus pneumoniae clinical isolates by broth dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007).
AID95555Minimum inhibitory concentration against Klebsiella (X26)1989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
3-Sulfonyl-1-carba-1-dethiacephems.
AID208287Minimum inhibitory concentration against Park strain of Streptococcus pneumoniae1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID207822Minimum inhibitory concentration against S13E strain of Staphylococcus aureus1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID561822Ratio of fAUC in muscle to fAUC in plasma of healthy human at 500 mg, po administered at tablet formulation with immediate release by microdialysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID325156Antimicrobial activity against Haemophilus parasuis BB 10232007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Beta-lactam resistance in Haemophilus parasuis Is mediated by plasmid pB1000 bearing blaROB-1.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1399262Antimicrobial activity against Escherichia coli BW25113 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID561106Antibacterial activity against Pasteurella multocida BB1040 harboring plasmid pB1000 bearing blaROB-1 gene and plasmid pB9956 bearing tetH gene by CLSI M31-A3 broth microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Multiresistance in Pasteurella multocida is mediated by coexistence of small plasmids.
AID85964Compound was evaluated for inhibitory activity against 76 Haemophilus influenzae beta-lactamase1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
3-trifluoromethylcarbacephems: synthesis of broad spectrum antibacterial compounds.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID486732Antimicrobial activity against Staphylococcus aureus after 24 hrs2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Synthesis and antimicrobial activity of cholic acid hydrazone analogues.
AID200335Compound was evaluated for inhibitory activity against X514 Salmonella1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
3-trifluoromethylcarbacephems: synthesis of broad spectrum antibacterial compounds.
AID1219875Inhibition of recombinant human ABCC4 expressed in baculovirus infected insect Sf21 cell plasma membrane vesicles assessed as inhibition of transporter-mediated [3H]-estradiol-17beta-glucuronide uptake by liquid scintillation counting analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Oral availability of cefadroxil depends on ABCC3 and ABCC4.
AID535679Antimicrobial activity against beta-lactamase negative Haemophilus influenzae expressing fst1 gene assessed as resistant isolates by microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Genotypic versus phenotypic characterization, with respect to beta-lactam susceptibility, of Haemophilus influenzae isolates exhibiting decreased susceptibility to beta-lactam resistance markers.
AID561834AUC in plasma of healthy human at 500 mg, po administered at tablet formulation with immediate release by microdialysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
AID574559Antibacterial activity against ROB-1 producing ICE- negative Haemophilus influenzae H23 by Etest method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
blaROB-1 presence on pB1000 in Haemophilus influenzae is widespread, and variable cefaclor resistance is associated with altered penicillin-binding proteins.
AID70105Compound was evaluated for inhibitory activity against TEM Escherichia coli beta-lactamase1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
3-trifluoromethylcarbacephems: synthesis of broad spectrum antibacterial compounds.
AID132394Efficacy against mouse infected ip with C203 strain of Streptococcus pyogenes, administered sc to 19-21-g random sex ICR mice at 1 hr and 5 hr1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID529619Antibacterial activity against Beta-lactamase positive Haemophilus influenzae assessed as susceptible isolates after 20 to 24 hrs by Etest method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Low beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains are best detected by testing amoxicillin susceptibility by the broth microdilution method.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID438298Inhibition of penicillin-resistant Streptococcus pneumoniae 5204 PBP2X preincubated for 4 hrs before addition of substrate (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.
AID68523Minimum inhibitory concentration against Enterobacter cloacae (265A beta-lactamase containing)1989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
3-Sulfonyl-1-carba-1-dethiacephems.
AID208928Antibacterial activity in mice infected with Streptococcus pneumoniae Park1 by oral administration1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Orally absorbable cephalosporin antibiotics. 1. Structure-activity relationships of benzothienyl- and naphthylglycine derivatives of 7-aminodeacetoxycephalosporanic acid.
AID94126In vitro minimal inhibitory concentration (MIC) in brain-heart infusion broth in the presence of hog liver esterase(1:1.5) in Klebsiella pneumoniae 0091990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporins to carbapenems: 1-oxygenated carbapenems and carbapenams.
AID486733Antimicrobial activity against Enterococcus faecalis after 24 hrs2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Synthesis and antimicrobial activity of cholic acid hydrazone analogues.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID561825fAUC in plasma of healthy human at 500 mg, po administered at tablet formulation with maximum release by microdialysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
AID561105Antibacterial activity against Pasteurella multocida BB1039 harboring plasmid pB1000 bearing blaROB-1 gene and plasmid pB9956 bearing tetH gene by CLSI M31-A3 broth microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Multiresistance in Pasteurella multocida is mediated by coexistence of small plasmids.
AID207833Minimum inhibitory concentration against X1.1 strain of Staphylococcus aureus1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID535344Antimicrobial activity against Streptococcus pneumoniae clinical isolates assessed as resistant isolates by broth dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007).
AID511289Antibacterial activity against Escherichia coli DH5alpha pB-ges-12010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID68035Compound was evaluated for inhibitory activity against 265a Enterobacter cloacae beta-lactamase1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
3-trifluoromethylcarbacephems: synthesis of broad spectrum antibacterial compounds.
AID574572Antibacterial activity against ROB-1 producing ICE- negative Haemophilus influenzae H23 by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
blaROB-1 presence on pB1000 in Haemophilus influenzae is widespread, and variable cefaclor resistance is associated with altered penicillin-binding proteins.
AID561821fAUC in muscle of healthy human at 500 mg, po administered at tablet formulation with immediate release by microdialysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
AID67551Compound was evaluated for inhibitory activity against EB17 Enterobacter aerogenes1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
3-trifluoromethylcarbacephems: synthesis of broad spectrum antibacterial compounds.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1399255Antimicrobial activity against Enterococcus faecalis ATCC 33186 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID575340Antimicrobial activity against Listeria monocytogenes EGD-e at 30 ug after 16 hrs by disk diffusion assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
The ABC transporter AnrAB contributes to the innate resistance of Listeria monocytogenes to nisin, bacitracin, and various beta-lactam antibiotics.
AID74716In vitro antibacterial activity was determined by 2 fold serial agar dilution method with multilocular device in gram positive bacteria1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Synthesis and antibacterial activities of new (alpha-hydrazinobenzyl)cephalosporins.
AID1399276Antimicrobial activity against Escherichia coli isolate SJ 4 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID293551Antibacterial activity against Salmonella typhi MTCC 733 after 24 hrs by agar dilution assay2007European journal of medicinal chemistry, Jun, Volume: 42, Issue:6
Organoiodine(III) mediated synthesis of 3,9-diaryl- and 3,9-difuryl-bis-1,2,4-triazolo[4,3-a][4,3-c]pyrimidines as antibacterial agents.
AID132261Efficacy against mouse infected ip with 3055 strain of Staphylococcus aureus, administered sc to 19-21-g random sex ICR mice at 1 hr and 5 hr1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID205556Minimum inhibitory concentration against Staphylococcus aureus (X1.1)1989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
3-Sulfonyl-1-carba-1-dethiacephems.
AID290191Antibacterial activity against Bacillus subtilis MTCC 121 by agar dilution method2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and characterization of cobalt(II), nickel(II), copper(II) and zinc(II) complexes with Schiff base derived from 4-amino-3-mercapto-6-methyl-5-oxo-1,2,4-triazine.
AID103831In vitro minimal inhibitory concentration (MIC) in brain-heart infusion broth in the presence of hog liver esterase(1:1.5) in Morganella morganii 0011990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporins to carbapenems: 1-oxygenated carbapenems and carbapenams.
AID529744Antibacterial activity against Beta-lactamase positive Haemophilus influenzae harboring fst1 mutant gene assessed as susceptible isolates after 20 to 24 hrs by Etest method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Low beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains are best detected by testing amoxicillin susceptibility by the broth microdilution method.
AID207141Antibacterial activity in mice infected with Staphylococcus aureus 30551985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Orally absorbable cephalosporin antibiotics. 1. Structure-activity relationships of benzothienyl- and naphthylglycine derivatives of 7-aminodeacetoxycephalosporanic acid.
AID210366In vitro antibacterial activity against the gram-positive bacteria, penicillin sensitive Streptococcus pneumoniae (3272)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID535362Antimicrobial activity against Haemophilus influenzae clinical isolates assessed as susceptible isolates by broth dilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007).
AID405306Antibacterial activity against beta-lactamase nonproducing ampicillin susceptible Haemophilus influenzae isolate assessed as percent resistant isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.
AID486729Antimicrobial activity against Escherichia coli after 24 hrs2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Synthesis and antimicrobial activity of cholic acid hydrazone analogues.
AID561103Antibacterial activity against Pasteurella multocida BB1037 harboring plasmid pB1000 bearing blaROB-1 gene and plasmid pB1005 bearing strA, sul2 genes by CLSI M31-A3 broth microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Multiresistance in Pasteurella multocida is mediated by coexistence of small plasmids.
AID86140Minimum inhibitory concentration against Haemophilus influenzae (C.L.)1989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
3-Sulfonyl-1-carba-1-dethiacephems.
AID325159Antimicrobial activity against Escherichia coli2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Beta-lactam resistance in Haemophilus parasuis Is mediated by plasmid pB1000 bearing blaROB-1.
AID681115TP_TRANSPORTER: inhibition of Gly-Sar uptake (pH6.0) in Caco-2 cells2005European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Jan, Volume: 59, Issue:1
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
AID1399261Antimicrobial activity against Enterobacter cloacae ATCC 13047 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID208959Antibacterial activity in mice infected with Streptococcus pyogenes C203 after oral administration1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Orally absorbable cephalosporin antibiotics. 1. Structure-activity relationships of benzothienyl- and naphthylglycine derivatives of 7-aminodeacetoxycephalosporanic acid.
AID543411Antimicrobial activity against Shigella sonnei UIH-1 expressing beta-lactamase CTX-M-64 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID574562Antibacterial activity against ROB-1 and TEM-1 producing ICE- positive Haemophilus influenzae F49 harboring D350N, V547I and N569S mutations in PBP3 by Etest method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
blaROB-1 presence on pB1000 in Haemophilus influenzae is widespread, and variable cefaclor resistance is associated with altered penicillin-binding proteins.
AID561109Antibacterial activity against Pasteurella multocida BB1043 harboring plasmid pB1000 bearing blaROB-1 gene and plasmid pB9956 bearing tetH gene by CLSI M31-A3 broth microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Multiresistance in Pasteurella multocida is mediated by coexistence of small plasmids.
AID681114TP_TRANSPORTER: inhibition of Gly-Sar uptake (pH6.0) in SKPT cells2005European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Jan, Volume: 59, Issue:1
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
AID125252Compound was evaluated for inhibitory activity against PR15 Morganella morganii1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
3-trifluoromethylcarbacephems: synthesis of broad spectrum antibacterial compounds.
AID1399256Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 29213 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID529614Antibacterial activity against Beta-lactamase negative Haemophilus influenzae assessed as resistant isolates after 20 to 24 hrs by Etest method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Low beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains are best detected by testing amoxicillin susceptibility by the broth microdilution method.
AID571939Antimicrobial activity against Escherichia coli MC4100 expressing promoterless beta-lactamase GES-1 by Etest2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter.
AID561108Antibacterial activity against Pasteurella multocida BB1042 harboring plasmid pB1000 bearing blaROB-1 gene and plasmid pB9956 bearing tetH gene by CLSI M31-A3 broth microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Multiresistance in Pasteurella multocida is mediated by coexistence of small plasmids.
AID394492Antimicrobial activity against Escherichia coli MC4100 harboring pA-acc4 plasmid by agar dilution technique2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID561100Antibacterial activity against Pasteurella multocida BB1034 harboring plasmid pB1000 bearing blaROB-1 gene and plasmid pB1001 bearing tetB gene by CLSI M31-A3 broth microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Multiresistance in Pasteurella multocida is mediated by coexistence of small plasmids.
AID210362In vitro antibacterial activity against the gram-positive bacteria, penicillin resistant Streptococcus pneumoniae (4629)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID1399266Antimicrobial activity against Proteus mirabilis ATCC 25933 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID486731Antimicrobial activity against Enterobacter aerogenes after 24 hrs2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Synthesis and antimicrobial activity of cholic acid hydrazone analogues.
AID293552Antibacterial activity against Staphylococcus epidermidis MTCC 2639 after 24 hrs by agar dilution assay2007European journal of medicinal chemistry, Jun, Volume: 42, Issue:6
Organoiodine(III) mediated synthesis of 3,9-diaryl- and 3,9-difuryl-bis-1,2,4-triazolo[4,3-a][4,3-c]pyrimidines as antibacterial agents.
AID68344In vitro inhibitory activity against Enterobacter cloacae EB51990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Comparative reactivity of 1-carba-1-dethiacephalosporins with cephalosporins.
AID293553Antibacterial activity against Escherichia coli MTCC 51 after 24 hrs by agar dilution assay2007European journal of medicinal chemistry, Jun, Volume: 42, Issue:6
Organoiodine(III) mediated synthesis of 3,9-diaryl- and 3,9-difuryl-bis-1,2,4-triazolo[4,3-a][4,3-c]pyrimidines as antibacterial agents.
AID438297Inhibition of penicillin-sensitive Streptococcus pneumoniae R6 PBP2X preincubated for 1 hr before addition of substrate (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.
AID325157Antimicrobial activity against Haemophilus parasuis BB 10242007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Beta-lactam resistance in Haemophilus parasuis Is mediated by plasmid pB1000 bearing blaROB-1.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID210363In vitro antibacterial activity against the gram-positive bacteria, penicillin resistant Streptococcus pneumoniae (4630)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID26413Half-life is evaluated1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Comparative reactivity of 1-carba-1-dethiacephalosporins with cephalosporins.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID405310Antibacterial activity against beta-lactamase nonproducing ampicillin resistant Haemophilus influenzae isolate assessed as percent resistant isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.
AID95554Minimum inhibitory concentration against Klebsiella (KAE beta-lactamase containing)1989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
3-Sulfonyl-1-carba-1-dethiacephems.
AID574580Antibacterial activity against ROB-1 producing ICE- negative Haemophilus influenzae Rd transformant harboring plasmid PB1000 by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
blaROB-1 presence on pB1000 in Haemophilus influenzae is widespread, and variable cefaclor resistance is associated with altered penicillin-binding proteins.
AID561102Antibacterial activity against Pasteurella multocida BB1036 harboring plasmid pB1000 bearing blaROB-1 gene and plasmid pB1005 bearing strA, sul2 genes by CLSI M31-A3 broth microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Multiresistance in Pasteurella multocida is mediated by coexistence of small plasmids.
AID1399272Antimicrobial activity against Klebsiella pneumoniae isolate SJ 5 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID132396Efficacy against mouse infected ip with park strain of Streptococcus pneumoniae administered sc to 19-21-g random sex ICR mice at 1 hr and 5 hr1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID574577Antibacterial activity against ROB-1 producing ICE- negative Haemophilus influenzae F41 by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
blaROB-1 presence on pB1000 in Haemophilus influenzae is widespread, and variable cefaclor resistance is associated with altered penicillin-binding proteins.
AID1399254Antimicrobial activity against Bacillus cereus ATCC 14579 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID1209735Inhibition of mouse OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake at 500 uM over 20 mins relative to untreated-control2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID206458In vitro antibacterial activity against the gram-positive bacteria, penicillin resistant Staphylococcus aureus (853)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID206417Antibacterial activity in mice infected with Staphylococcus aureus 3055 by subcutaneous administration1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Orally absorbable cephalosporin antibiotics. 1. Structure-activity relationships of benzothienyl- and naphthylglycine derivatives of 7-aminodeacetoxycephalosporanic acid.
AID535346Antimicrobial activity against Streptococcus pneumoniae clinical isolates assessed as susceptible isolates by PK/PD technique2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007).
AID1399258Antimicrobial activity against Streptococcus pneumoniae R6 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID205886Minimum inhibitory concentration against Epil strain of Staphylococcus epidermidis1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID560490Antibacterial activity against 5 x 10'5 CFU/ml Escherichia coli MC4100 harboring plasmid ACYC184 by microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase.
AID574574Antibacterial activity against ROB-1 producing ICE- positive Haemophilus influenzae F45 harboring D350N, V547I and N569S mutations in PBP3 by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
blaROB-1 presence on pB1000 in Haemophilus influenzae is widespread, and variable cefaclor resistance is associated with altered penicillin-binding proteins.
AID95890In vitro inhibitory activity against Klebsiella X261990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Comparative reactivity of 1-carba-1-dethiacephalosporins with cephalosporins.
AID574569Antibacterial activity against ROB-1 producing ICE- negative Haemophilus influenzae F50 by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
blaROB-1 presence on pB1000 in Haemophilus influenzae is widespread, and variable cefaclor resistance is associated with altered penicillin-binding proteins.
AID529628Antibacterial activity against Beta-lactamase positive Haemophilus influenzae harboring fst1 mutant gene assessed as susceptible isolates after 20 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Low beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains are best detected by testing amoxicillin susceptibility by the broth microdilution method.
AID571936Antimicrobial activity against Escherichia coli MC4100 harboring weak promoter and active promoter P2 in beta-lactamase GES-1 by Etest2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter.
AID1399252Antimicrobial activity against Bacillus subtilis ATCC 23857 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID561820fAUC in plasma of healthy human at 500 mg, po administered at tablet formulation with immediate release by microdialysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
AID681608TP_TRANSPORTER: inhibition of Gly-Sar uptake (Gly-Sar: 20 uM) in PEPT1-expressing CHO cells1999Journal of pharmaceutical sciences, Mar, Volume: 88, Issue:3
CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs.
AID1070215Inhibition of Trichomonas vaginalis uridine nucleoside ribohydrolase using 5-fluorouridine as substrate at 0.04 to 200 uM after 40 mins by NMR spectrometric analysis2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Identification of proton-pump inhibitor drugs that inhibit Trichomonas vaginalis uridine nucleoside ribohydrolase.
AID209290Compound was evaluated for inhibitory activity against C203 Streptococcus pyogenes Gp.A1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
3-trifluoromethylcarbacephems: synthesis of broad spectrum antibacterial compounds.
AID372667Antimicrobial activity against Pseudomonas aeruginosa MTCC 3541 after 24 hrs by agar dilution assay2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
Synthesis and antibacterial activity of some new 2,3-dimethoxy-3-hydroxy-2-(1-phenyl-3-aryl-4-pyrazolyl)chromanones.
AID561833Ratio of fAUC in muscle to fAUC in plasma of healthy human at 750 mg. po administered at tablet formulation with maximum release by microdialysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
AID162920Minimum inhibitory concentration against Proteus morganii (PR 15)1989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
3-Sulfonyl-1-carba-1-dethiacephems.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID64044In vitro minimal inhibitory concentration (MIC) in brain-heart infusion broth in the presence of hog liver esterase(1:1.5) in Escherichia coli 1291990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporins to carbapenems: 1-oxygenated carbapenems and carbapenams.
AID574570Antibacterial activity against ROB-1 producing ICE- positive Haemophilus influenzae F48 by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
blaROB-1 presence on pB1000 in Haemophilus influenzae is widespread, and variable cefaclor resistance is associated with altered penicillin-binding proteins.
AID68036Compound was evaluated for inhibitory activity against EB5 Enterobacter cloacae1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
3-trifluoromethylcarbacephems: synthesis of broad spectrum antibacterial compounds.
AID132260Efficacy against mouse infected ip with 3055 strain of Staphylococcus aureus, administered po to 19-21-g random sex ICR mice at 1 hr and 5 hr1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID67550Compound was evaluated for inhibitory activity against C32 Enterobacter aerogenes1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
3-trifluoromethylcarbacephems: synthesis of broad spectrum antibacterial compounds.
AID1399271Antimicrobial activity against Klebsiella pneumoniae isolate SJ 4 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1399279Antimicrobial activity against Escherichia coli ATCC 35218 expressing TEM-1 beta lactamases after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID574561Antibacterial activity against ROB-1 producing ICE- positive Haemophilus influenzae F45 harboring D350N, V547I and N569S mutations in PBP3 by Etest method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
blaROB-1 presence on pB1000 in Haemophilus influenzae is widespread, and variable cefaclor resistance is associated with altered penicillin-binding proteins.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID325160Antimicrobial activity against Escherichia coli pB1000 expressing ROB1 beta lactamase2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Beta-lactam resistance in Haemophilus parasuis Is mediated by plasmid pB1000 bearing blaROB-1.
AID325150Antimicrobial activity against Haemophilus parasuis ATCC 194172007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Beta-lactam resistance in Haemophilus parasuis Is mediated by plasmid pB1000 bearing blaROB-1.
AID70104Compound was evaluated for inhibitory activity against EC14 Escherichia coli sensitive1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
3-trifluoromethylcarbacephems: synthesis of broad spectrum antibacterial compounds.
AID64043In vitro minimal inhibitory concentration (MIC) in brain-heart infusion broth in the presence of hog liver esterase(1:1.5) in Escherichia coli 2661990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporins to carbapenems: 1-oxygenated carbapenems and carbapenams.
AID205204Compound was evaluated for inhibitory activity against X99 Serratia1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
3-trifluoromethylcarbacephems: synthesis of broad spectrum antibacterial compounds.
AID405311Antibacterial activity against beta-lactamase producing amoxicillin-clavulanic acid-resistant Haemophilus influenzae isolate assessed as percent susceptible isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.
AID405308Antibacterial activity against beta-lactamase positive ampicillin resistant Haemophilus influenzae isolate assessed as percent resistant isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.
AID290192Antibacterial activity against Salmonella typhi MTCC 733 by agar dilution method2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and characterization of cobalt(II), nickel(II), copper(II) and zinc(II) complexes with Schiff base derived from 4-amino-3-mercapto-6-methyl-5-oxo-1,2,4-triazine.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1399264Antimicrobial activity against Klebsiella pneumoniae ATCC 33495 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1399273Antimicrobial activity against Escherichia coli isolate SJ 1 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID210365In vitro antibacterial activity against the gram-positive bacteria, penicillin resistant Streptococcus pneumoniae (4636)1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.
AID561110Antibacterial activity against Pasteurella multocida BB1044 harboring plasmid pB1000 bearing blaROB-1 gene, plasmid 1006 bearing tetO gene and plasmid pB1005 bearing strA, sul2 genes by CLSI M31-A3 broth microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Multiresistance in Pasteurella multocida is mediated by coexistence of small plasmids.
AID543423Antimicrobial activity against Escherichia coli XL-1 Blue transconjugant harboring beta-lactamase CTX-M-64 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID1653081Antibacterial activity against Bacillus pumilus2019European journal of medicinal chemistry, Feb-15, Volume: 164Isatin derivatives and their anti-bacterial activities.
AID200256In vitro minimal inhibitory concentration (MIC) in brain-heart infusion broth in the presence of hog liver esterase(1:1.5) in Staphylococcus aureus 4001990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporins to carbapenems: 1-oxygenated carbapenems and carbapenams.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1399257Antimicrobial activity against methicillin-resistant Staphylococcus aureus NRS70 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID574564Antibacterial activity against ROB-1 producing ICE- negative Haemophilus influenzae F41 by Etest method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
blaROB-1 presence on pB1000 in Haemophilus influenzae is widespread, and variable cefaclor resistance is associated with altered penicillin-binding proteins.
AID133285Minimum inhibitory concentration against mouse infected with 3055 strain of Staphylococcus aureus1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID69199Minimum inhibitory concentration against EC14 strain Escherichia coli1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.
AID571932Antimicrobial activity against Escherichia coli MC4100 harboring a weak promoter in beta-lactamase GES-1 by Etest2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter.
AID574575Antibacterial activity against ROB-1 producing ICE- positive Haemophilus influenzae F49 harboring D350N, V547I and N569S mutations in PBP3 by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
blaROB-1 presence on pB1000 in Haemophilus influenzae is widespread, and variable cefaclor resistance is associated with altered penicillin-binding proteins.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (839)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990327 (38.97)18.7374
1990's276 (32.90)18.2507
2000's124 (14.78)29.6817
2010's84 (10.01)24.3611
2020's28 (3.34)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 7.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index7.28 (24.57)
Research Supply Index7.07 (2.92)
Research Growth Index4.35 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (7.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials260 (28.29%)5.53%
Reviews48 (5.22%)6.00%
Case Studies64 (6.96%)4.05%
Observational0 (0.00%)0.25%
Other547 (59.52%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]